var title_f15_38_15968="Lymph nodes neck child PI";
var content_f15_38_15968=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Lymph nodes in a child's neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 502px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymph nodes are pea-shaped organs. This drawing shows where the lymph nodes in a child&rsquo;s neck are.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_38_15968=[""].join("\n");
var outline_f15_38_15968=null;
var title_f15_38_15969="Aorta Doppler waveform";
var content_f15_38_15969=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Aorta Doppler waveform",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Laminar, pulsatile flow in the abdominal aorta is recorded with pulsed wave Doppler imaging. The signal demonstrates a narrow envelope during systole. The maximal peak systolic velocity of the flow is approximately 100 cm/sec. Note, however, that the ultrasound beam is not parallel to the flow direction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Feigenbaum H, Armstrong WF, Ryan T. Echocardiography, Sixth Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_38_15969=[""].join("\n");
var outline_f15_38_15969=null;
var title_f15_38_15970="Ear lesion of chronic HSV";
var content_f15_38_15970=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic herpes simplex of the ear and neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extensive lesion with ulceration involving the posterior ear and neck due to herpes simplex in a patient with HIV.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lee T Nesbitt Jr, MD.&nbsp;The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds) Williams and Wilkins, Baltimore 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_38_15970=[""].join("\n");
var outline_f15_38_15970=null;
var title_f15_38_15971="Oropharynx of a snorer I";
var content_f15_38_15971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oropharynx of a snorer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The photograph is from a snoring patient in whom obstructive sleep apnea was excluded by polysomnography. Erythema and edema of the uvula are present, probably secondary to the tissue vibration that accompanies the snoring sound.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_38_15971=[""].join("\n");
var outline_f15_38_15971=null;
var title_f15_38_15972="Brinzolamide: Patient drug information";
var content_f15_38_15972=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Brinzolamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/35/29235?source=see_link\">",
"     see \"Brinzolamide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Azopt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Azopt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high eye pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701648",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to brinzolamide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any eye problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 10 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11424 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_38_15972=[""].join("\n");
var outline_f15_38_15972=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142340\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142341\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023845\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023847\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023846\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023851\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023852\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023854\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023849\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023850\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023855\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023856\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/35/29235?source=related_link\">",
"      Brinzolamide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_38_15973="Glyburide: Patient drug information";
var content_f15_38_15973=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Glyburide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     see \"Glyburide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/22/37222?source=see_link\">",
"     see \"Glyburide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DiaBeta&reg;;",
"     </li>",
"     <li>",
"      Glynase&reg; PresTab&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F176699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Glyburide&reg;;",
"     </li>",
"     <li>",
"      DiaBeta&reg;;",
"     </li>",
"     <li>",
"      Dom-Glyburide;",
"     </li>",
"     <li>",
"      Euglucon&reg;;",
"     </li>",
"     <li>",
"      Med-Glybe;",
"     </li>",
"     <li>",
"      Mylan-Glybe;",
"     </li>",
"     <li>",
"      Novo-Glyburide;",
"     </li>",
"     <li>",
"      Nu-Glyburide;",
"     </li>",
"     <li>",
"      PMS-Glyburide;",
"     </li>",
"     <li>",
"      PRO-Glyburide;",
"     </li>",
"     <li>",
"      ratio-Glyburide;",
"     </li>",
"     <li>",
"      Riva-Glyburide;",
"     </li>",
"     <li>",
"      Sandoz-Glyburide;",
"     </li>",
"     <li>",
"      Teva-Glyburide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10013833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to control blood sugar in pregnant women.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702208",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to glyburide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem or type 1 diabetes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 80 or older, use this drug with care. You could be more sensitive to low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be used alone or with other high blood sugar (diabetes) drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695917",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with the first meal of the day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12513 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_38_15973=[""].join("\n");
var outline_f15_38_15973=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176698\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176699\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013833\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013835\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013834\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013839\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013840\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013842\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013837\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013838\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013843\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013844\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=related_link\">",
"      Glyburide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/22/37222?source=related_link\">",
"      Glyburide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_38_15974="Nasal bone and cartilage";
var content_f15_38_15974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75148&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 589px\">",
"   <div class=\"ttl\">",
"    Relationship of the bones and cartilages of the nose",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 569px; height: 500px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Parsons JT, Stringer SP, Mancuso AA, Million RR. Nasal vestibule, nasal cavity, and paranasal sinuses. In: Million RR, Cassisi NJ (Eds). Management of Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia: J.B. Lippincott Company, 1994. Copyright &copy; 1994 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_38_15974=[""].join("\n");
var outline_f15_38_15974=null;
var title_f15_38_15975="Ectopic atrial rhythm tutorial";
var content_f15_38_15975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1046px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ectopic atrial rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 105px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ectopic atrial rhythm occurs when the dominant pacemaker is an ectopic focus in the atrium. The direction of atrial activation may be altered when an atrial rhythm is present since the pacemaker focus is within the atrial myocardium. In this tracing, the P wave is inverted due to retrograde atrial activation from a pacemaker focus in the low atrium, the area of the coronary sinus, or the left atrium. The QRS complexes of an atrial tachycardia resemble those seen during sinus rhythm, since myocardial activation is via the His-Purkinje system.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_38_15975=[""].join("\n");
var outline_f15_38_15975=null;
var title_f15_38_15976="Lisinopril: Pediatric drug information";
var content_f15_38_15976=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lisinopril: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"    see \"Lisinopril: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/32/9734?source=see_link\">",
"    see \"Lisinopril: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Prinivil&reg;;",
"     </li>",
"     <li>",
"      Zestril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Lisinopril&reg;;",
"     </li>",
"     <li>",
"      CO Lisinopril;",
"     </li>",
"     <li>",
"      Dom-Lisinopril;",
"     </li>",
"     <li>",
"      JAMP-Lisinopril;",
"     </li>",
"     <li>",
"      Mint-Lisinopril;",
"     </li>",
"     <li>",
"      Mylan-Lisinopril;",
"     </li>",
"     <li>",
"      PMS-Lisinopril;",
"     </li>",
"     <li>",
"      Prinivil&reg;;",
"     </li>",
"     <li>",
"      PRO-Lisinopril;",
"     </li>",
"     <li>",
"      RAN&trade;-Lisinopril;",
"     </li>",
"     <li>",
"      ratio-Lisinopril;",
"     </li>",
"     <li>",
"      ratio-Lisinopril P;",
"     </li>",
"     <li>",
"      ratio-Lisinopril Z;",
"     </li>",
"     <li>",
"      Riva-Lisinopril;",
"     </li>",
"     <li>",
"      Sandoz-Lisinopril;",
"     </li>",
"     <li>",
"      Teva-Lisinopril (Type P);",
"     </li>",
"     <li>",
"      Teva-Lisinopril (Type Z);",
"     </li>",
"     <li>",
"      Zestril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Angiotensin-Converting Enzyme (ACE) Inhibitor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"      see \"Lisinopril: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypertension: Note:",
"     </b>",
"     Dosage must be titrated according to patient's response;",
"     <b>",
"      reduce dose by 50% in patients with hyponatremia, hypovolemia, severe CHF, decreased renal function, or receiving diuretics",
"     </b>",
"     . If possible, discontinue diuretics 2-3 days prior to initiating lisinopril; restart diuretic, if needed, after blood pressure is stable:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants: Limited data available: Oral: Initial: 0.07-0.1 mg/kg/dose once daily; may increase at &ge;2 weeks intervals; maximum daily dose: 0.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ; dosing based on a retrospective study of pediatric patients (n=123; 59 with hypertension; age range: 2 months to 18 years) which initiated therapy in the hospital to allow for close observation; median maximum dose in patients 1 month to &lt;2 years (n=13): 0.159 mg/kg/day; (Raes, 2007); further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &lt;6 years: Limited data available: Oral: Initial: 0.07-0.1 mg/kg/dose once daily; maximum initial daily dose: 5 mg/",
"     <b>",
"      day",
"     </b>",
"     ; increase dose at 1- to 2-week intervals; maximum daily dose: 0.6 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     or 40 mg/",
"     <b>",
"      day",
"     </b>",
"     (NHBPEP, 2004; NHLBI, 2011; Raes, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;6 years and Adolescents: Oral: Initial: 0.07-0.1 mg/kg/dose once daily; maximum initial daily dose: 5 mg/",
"     <b>",
"      day",
"     </b>",
"     ; increase dose at 1- to 2-week intervals; maximum daily dose: 0.6 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     or 40 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Proteinuria (mild IgA nephropathy):",
"     </b>",
"     Children &ge;4 years and Adolescents: Limited data available: Oral: Initial: 0.2 mg/kg/dose once daily (maximum initial dose: 10 mg) for 7 days, then increase to 0.4 mg/kg/dose once daily (maximum dose: 20 mg); dosing based on a pilot study of 40 pediatric patients (mean age: 11.4 years; range: 4-15 years) who during a 2-year treatment period showed statistically significant resolution of proteinuria in 82% of patients; five patients developed dizziness during treatment period and four of them required dosage reduction (50% to 75%) (Nakanishi, 2008); further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Renal protection (diabetes mellitus or renal parenchymal disease):",
"     </b>",
"     Infants, Children, and Adolescents: Limited data available: Oral: Initial: 0.1 mg/kg/dose once daily; maximum initial daily dose: 5 mg/day; dosing based on a retrospective study of pediatric patients (n=123 of which 60 had either DM or renal parenchymal disease; age range: 2 months to 18 years); the protocol included therapy initiation within the hospital to allow for close observation initially; median maximum dose: 0.135 mg/kg/day (Raes, 2007); further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Oral: Initial: 2.5-5 mg once daily; then increase by no more than 10 mg increments at intervals no less than 2 weeks to a maximum daily dose of 40 mg. Usual maintenance: 5-40 mg/day as a single dose. Target dose: 20-40 mg once daily (ACC/AHA 2009 Heart Failure Guidelines).",
"     <b>",
"      Note:",
"     </b>",
"     If patient has hyponatremia (serum sodium &lt;130 mEq/L) or renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute or creatinine &gt;3 mg/dL), then initial dose should be 2.5 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Usual dosage range (JNC 7): 10-40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Not maintained on diuretic: Initial: 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintained on diuretic: Initial: 5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Antihypertensive effect may diminish toward the end of the dosing interval especially with doses of 10 mg/day. An increased dose may aid in extending the duration of antihypertensive effect. Doses up to 80 mg/day have been used, but do not appear to give greater effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Patients taking diuretics should have them discontinued 2-3 days prior to initiating lisinopril if possible. Restart diuretic after blood pressure is stable if needed. If diuretic cannot be discontinued prior to therapy, begin with 5 mg with close supervision until stable blood pressure. In patients with hyponatremia (&lt;130 mEq/L), start dose at 2.5 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acute myocardial infarction (within 24 hours in hemodynamically stable patients):",
"     </b>",
"     Oral: 5 mg immediately, then 5 mg at 24 hours, 10 mg at 48 hours, and 10 mg every day thereafter for 6 weeks. Patients should continue to receive standard treatments such as thrombolytics, aspirin, and beta-blockers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer labeling: Children &ge;6 years and Adolescents &le;16 years: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Use is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternate dosing (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     GFR &gt;50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     :  No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     GFR 10-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 50% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     GFR &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 25% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Intermittent hemodialysis: Administer 25% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Peritoneal dialysis (PD):  Administer 25% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Continuous renal replacement therapy (CRRT): Administer 50% of usual dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Manufacturer&rsquo;s labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Heart failure: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute or serum creatinine &gt;3 mg/dL: Initial: 2.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hypertension: Initial doses should be modified and upward titration should be cautious, based on response (maximum: 40 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: Initial: 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: Initial: 5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Hemodialysis: Initial: 2.5 mg/day; dialyzable (50%)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F189166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prinivil&reg;: 5 mg, 10 mg, 20 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zestril&reg;: 2.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zestril&reg;: 5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zestril&reg;: 10 mg, 20 mg, 30 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to food",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, either alone or in combination with other antihypertensive agents (FDA approved in ages 6-16 years and adults); adjunctive therapy in treatment of heart failure (HF) (FDA approved in adults); treatment of acute myocardial infarction (MI) within 24 hours in hemodynamically-stable patients to improve survival (FDA approved in adults); has also been used for the treatment of proteinuria associated with IgA nephropathy and for its reno-protective effects in patients with diabetes mellitus and renal parenchymal disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F189246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lisinopril may be confused with fosinopril, Lioresal&reg;, Lipitor&reg;, RisperDAL&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Prinivil&reg; may be confused with Plendil&reg;, Pravachol&reg;, Prevacid&reg;, PriLOSEC&reg;, Proventil&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zestril&reg; may be confused with Desyrel, Restoril&trade;, Vistaril&reg;, Zegerid&reg;, Zerit&reg;, Zetia&reg;, Zostrix&reg;, ZyPREXA&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acepril [Malaysia] may be confused with Accupril which is a brand name for quinapril [U.S.]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acepril: Brand name for lisinopril [Malaysia], but also the brand name for captopril [Great Britain]; enalapril [Hungary, Switzerland]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F189244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Higher rates of adverse reactions have generally been noted in patients with heart failure. However, the frequency of adverse effects associated with placebo is also increased in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, orthostatic effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Decreased hemoglobin (small)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chest pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased; deterioration in renal function (in patients with bilateral renal artery stenosis or hypovolemia); serum creatinine increased (often transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute renal failure, alopecia, anaphylactoid reactions, angioedema, anuria, arrhythmia, arthralgia, arthritis, asthma, ataxia, atrial fibrillation, atrial tachycardia, azotemia, bone marrow suppression, bradycardia, cardiac arrest, cutaneous pseudolymphoma, diabetes mellitus, eosinophilia, eosinophilic pneumonitis, erythrocyte sedimentation rate increased, gout, hemolytic anemia, hemoptysis, hepatic necrosis, hepatitis, herpes zoster, hypersomnia, hyponatremia, interstitial nephritis, intestinal angioedema, leukopenia, lung neoplasms (malignant), memory impairment, MI, mood changes, neutropenia, oliguria, orthostatic hypotension, pancreatitis, pemphigus, peripheral neuropathy, photosensitivity, pleural effusion, pneumonia, positive ANA, psoriasis, pulmonary embolism, pulmonary infarction, SIADH, skin infections, Stevens-Johnson syndrome, stroke, syncope, systemic lupus erythematosus, thrombocytopenia, TIA, toxic epidermal necrolysis, urinary tract infection, vasculitis, ventricular tachycardia, viral infection, vision loss, visual hallucinations (Doane, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lisinopril, any component, or other ACE inhibitors; patients with idiopathic or hereditary angioedema or a history of angioedema with previous ACE inhibitor use",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; dosage reduction may be necessary; avoid rapid dosage escalation which may lead to further renal impairment. Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution when initiating therapy and in volume-depleted patients; may cause symptomatic hypotension with or without syncope, usually with the first several doses; correct volume depletion prior to initiation; initiate lower doses in patients with sodium or volume depletion; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension alone is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation. Use caution in patients with ischemic heart disease or cerebrovascular disease during therapy initiation; observe closely due to the potential consequences posed by falling blood pressure (eg, MI, stroke); fluid replacement, may be required to restore blood pressure; therapy may then be resumed; discontinue therapy in patients whose hypotension recurs. Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia. Use with caution in patients with hypertrophic cardiomyopathy (HCM) and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause hyperkalemia; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts; use with caution, if at all, with these agents, and monitor potassium closely. Concurrent use of angiotensin receptor blockers (ARBs) may increase the risk of clinically significant adverse events (eg, renal dysfunction, hyperkalemia).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution before, during, or immediately after major surgery; cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release; use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. In pediatric patients, an isolated dry hacking cough lasting &gt;3 weeks was reported in 7 of 42 pediatric patients (17%) receiving ACE inhibitors (von Vigier, 2000); a review of pediatric randomized controlled ACE inhibitor trials reported a lower incidence of  3.2% (Baker-Smith, 2010). Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Angioedema can occur at any time during treatment (especially following first dose). The relative risk of angioedema with ACE inhibitors is higher within the first 30 days of use (compared to &gt;1 year of use), for Black Americans (compared to Whites), for lisinopril or enalapril (compared to captopril), and for patients previously hospitalized within 30 days (Brown, 1996). Angioedema may occur in the head, neck, extremities, or intestines; patients with angioedema of the intestines may present with abdominal pain (with or without nausea or vomiting); angioedema of the larynx, glottis, or tongue may cause airway obstruction, especially in patients with a history of airway surgery; prolonged monitoring may be required, even in patients with swelling of only the tongue (ie, without respiratory distress) because treatment with corticosteroids and antihistamines may not be sufficient; very rare fatalities have occurred with angioedema of the larynx or tongue; appropriate treatment (eg, establishing patent airway and/or SubQ epinephrine) should be readily available for patients with angioedema of larynx, glottis, or tongue, in whom airway obstruction is likely to occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Life-threatening anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (eg, bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     ACE inhibitor therapy has been associated with rare but potentially fatal cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia; higher risk for development of neutropenia is associated with renal impairment; risk is further increased in patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus). Onset of neutropenia is usually within 3 months of ACE inhibitor initiation; closely monitor CBC with differential for the first 3 months of therapy and periodically thereafter in these patients; neutrophil count generally returns to baseline within 2 weeks of discontinuation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     ACE inhibitor use has been associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs and initiate appropriate medical treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of Lisinopril.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1053666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food does not affect oral absorption. Limit salt substitutes or potassium-rich diet. Avoid natural licorice (causes sodium and water retention and increases potassium loss).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F189162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F189177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Lisinopril crosses the placenta; teratogenic effects may occur following maternal use during pregnancy. Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Their use in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant. ACE inhibitors are not recommended during pregnancy to treat maternal hypertension or heart failure. Use of an ACE inhibitor should also be avoided in any woman of reproductive age. Women who are planning a pregnancy should be considered for other medication options if an ACE inhibitor is currently prescribed or the ACE inhibitor should be discontinued as soon as possible once pregnancy is detected. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed to an ACE inhibitor",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, BUN, serum creatinine, renal function, urine dipstick for protein, serum potassium, WBC with differential, especially during first 3 months of therapy for patients with renal impairment and/or collagen vascular disease; monitor for angioedema and anaphylactoid reactions; hypovolemia and postural hypotension when beginning therapy, adjusting dosage, and on a regular basis throughout",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion; a CNS mechanism may also be involved in hypotensive effect as angiotensin II increases adrenergic outflow from CNS; vasoactive kallikreins may be decreased in conversion to active hormones by ACE inhibitors, thus reducing blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1053662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Antihyptensive effect: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Antihypertensive effect: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatric patients:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-15 years: 20% to 36% (Hogg, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-16 years: 28%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 25% (range: 6% to 60%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 11-13 hours; half-life increases with renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatric patients 6 months to 15 years: Median (range): 5-6 hours (Hogg, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Within 7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily urine as unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Removable by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/32/9734?source=see_link\">",
"      see \"Lisinopril: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit alcohol. Notify physician immediately if swelling of face, lips, tongue, or difficulty in breathing occurs; if these occur, do not take any more doses until a physician can be consulted. Notify physician if vomiting, diarrhea, excessive perspiration, dehydration, or persistent cough occurs. Do not use a salt substitute (potassium-containing) without physician advice. May cause dizziness, fainting, and lightheadedness, especially in first week of therapy; sit and stand up slowly. May cause rash. Report sore throat, fever, other signs of infection, or other side effects. This medication may cause injury and death to the developing fetus when used during pregnancy; women of childbearing potential should be informed of potential risk; consult prescriber for appropriate contraceptive measures; this medication should be discontinued as soon as possible once pregnancy is detected.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F189172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL lisinopril oral suspension may be made with tablets and a 1:1 mixture of Ora-Plus&reg; and Ora-Sweet&reg;. Crush ten 10 mg tablets in a mortar and reduce to a fine powder. Add small portions of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a graduated cylinder; rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Store in amber plastic prescription bottles; label \"shake well\". Stable for 13 weeks at room temperature or refrigerated (Nahata, 2004).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 1 mg/mL lisinopril oral suspension also be made with tablets, methylcellulose 1% with parabens, and simple syrup NF. Crush ten 10 mg tablets in a mortar and reduce to a fine powder. Add 7.7 mL of methylcellulose gel  and mix to a uniform paste; mix while adding the simple syrup in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a graduated cylinder; rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Store in amber plastic prescription bottles; label \"shake well\". Stable for 13 weeks refrigerated or 8 weeks at room temperature (Nahata, 2004).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 2 mg/mL lisinopril syrup may be made with powder (Sigma Chemical Company, St. Louis, MO) and simple syrup. Dissolve 1 g of lisinopril powder in 30 mL of distilled water. Mix while adding simple syrup in incremental proportions in a quantity sufficient to make 500 mL. Label \"shake well\" and \"refrigerate\". Stable for 30 days when stored in amber plastic prescription bottles at room temperature or refrigerated.",
"     <b>",
"      Note:",
"     </b>",
"     Although no visual evidence of microbial growth was observed, the authors recommend refrigeration to inhibit microbial growth (Webster, 1997).",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC and Morosco RS, \"Stability of Lisinopril in Two Liquid Dosage Forms,\"",
"     <i>",
"      Ann Pharmacother",
"     </i>",
"     , 2004, 38(3):396-9.",
"     <span class=\"pubmed-id\">",
"      14742834",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Prinivil&reg; prescribing information, Merck &amp; Co, Inc, Whitehouse Station, NJ, 2008.",
"    </div>",
"    <div class=\"reference\">",
"     Thompson KC, Zhao Z, Mazakas JM, et al, \"Characterization of an Extemporaneous Liquid Formulation of Lisinopril,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 2003, 60(1):69-74.",
"     <span class=\"pubmed-id\">",
"      12533979",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Webster AA, English BA, and Rose DJ, \"The Stability of Lisinopril as an Extemporaneous Syrup,\"",
"     <i>",
"      Intr J Pharmaceut Compound",
"     </i>",
"     , 1997, 1:352-3.",
"    </div>",
"    <div class=\"reference\">",
"     Zestril&reg; prescribing information, AstraZeneca Pharmaceuticals, Wilmington, DE, 2007.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baker-Smith CM, Benjamin DK Jr, Califf RM, et al, \"Cough in Pediatric Patients Receiving Angiotensin-Converting Enzyme Inhibitor Therapy or Angiotensin Receptor Blocker Therapy in Randomized Controlled Trials,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2010, 87(6):668-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15976/abstract-text/20130570/pubmed\" id=\"20130570\" target=\"_blank\">",
"        20130570",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown NJ, Ray WA, Snowden M, et al, &ldquo;Black Americans Have an Increased Rate of Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1996, 60(1):8-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15976/abstract-text/8689816/pubmed\" id=\"8689816\" target=\"_blank\">",
"        8689816",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15976/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hogg RJ, Delucchi A, Sakihara G, et al, \"A Multicenter Study of the Pharmacokinetics of Lisinopril in Pediatric Patients With Hypertension,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2007, 22(5):695-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15976/abstract-text/17216247/pubmed\" id=\"17216247\" target=\"_blank\">",
"        17216247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nakanishi K, Iijima K, Ishikura K, et al, \"Efficacy and Safety of Lisinopril for Mild Childhood IgA Nephropathy: A Pilot Study,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2009, 24(4):845-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15976/abstract-text/18825420/pubmed\" id=\"18825420\" target=\"_blank\">",
"        18825420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute, &ldquo;Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , 2011, National Institutes of Health. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15976/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raes A, Malfait F, Van Aken S, et al, \"Lisinopril in Paediatric Medicine: A Retrospective Chart Review of Long-Term Treatment in Children,\"",
"      <i>",
"       J Renin Angiotensin Aldosterone Syst",
"      </i>",
"      , 2007, 8(1):3-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15976/abstract-text/17487821/pubmed\" id=\"17487821\" target=\"_blank\">",
"        17487821",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raia JJ Jr, Barone JA, Byerly WG, et al, &ldquo;Angiotensin-Converting Enzymes Inhibitors: A Comparative Review,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1990, 24(5):506-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15976/abstract-text/2188439/pubmed\" id=\"2188439\" target=\"_blank\">",
"        2188439",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soffer B, Zhang Z, Miller K, et al, \"A Double-Blind, Placebo-Controlled, Dose-Response Study of the Effectiveness and Safety of Lisinopril for Children With Hypertension,\"",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 2003, 16(10):795-800.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15976/abstract-text/14553956/pubmed\" id=\"14553956\" target=\"_blank\">",
"        14553956",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      von Vigier RO, Mozzettini S, Truttmann AC, et al, &ldquo;Cough is Common in Children Prescribed Converting Enzyme Inhibitors,&rdquo;",
"      <i>",
"       Nephron",
"      </i>",
"      , 2000, 84(1):98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15976/abstract-text/10644922/pubmed\" id=\"10644922\" target=\"_blank\">",
"        10644922",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12558 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-1D88657B2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_38_15976=[""].join("\n");
var outline_f15_38_15976=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709016\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189191\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189192\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053655\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053648\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189166\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189151\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053659\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053658\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189246\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189244\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053664\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053647\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053646\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299611\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189160\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053666\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189162\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189177\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053654\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053645\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053662\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053663\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053652\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189172\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12558\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12558|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=related_link\">",
"      Lisinopril: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/32/9734?source=related_link\">",
"      Lisinopril: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_38_15977="Epidemiology, pathogenesis, and clinical features of schistosomiasis";
var content_f15_38_15977=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/38/15977/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/38/15977/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/38/15977/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/38/15977/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/38/15977/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/38/15977/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/38/15977/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/38/15977/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schistosomiasis is sometimes referred to as \"bilharziasis\" after Theodor Bilharz who identified the parasite first in 1852. Schistosomiasis is caused by infection with parasitic blood flukes known as schistosomes.",
"   </p>",
"   <p>",
"    Schistosomiasis can be associated with serious morbidity and mortality. Chronic complications are generally seen in those with a high parasite load, which usually occurs in individuals who live in endemic areas and have recurrent exposure. However, schistosomiasis can also cause complications in people with even brief exposures, such as travelers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, and clinical features of schistosomiasis will be reviewed here. The diagnosis, treatment, and prevention of these infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7398?source=see_link\">",
"     \"Diagnosis of schistosomiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14807?source=see_link\">",
"     \"Treatment and prevention of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCHISTOSOME SPECIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three major species and two less common species produce infection in humans:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the major species, S. mansoni and S. japonicum, can provoke intestinal and hepatic complications.",
"     </li>",
"     <li>",
"      S. haematobium predominantly leads to renal and bladder sequelae, although occasionally, it results in liver disease.",
"     </li>",
"     <li>",
"      The minor species include S. mekongi and S. intercalatum, both of which can also induce intestinal and liver disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mixed infections can also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that more than 200 million people worldwide have schistosomiasis and that the infection is responsible for more than 200,000 deaths annually [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/3\">",
"     3",
"    </a>",
"    ]. On a global scale, 1 in every 30 individuals has schistosomiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Schistosomiasis is associated with significant morbidity including anemia, chronic pain, diarrhea, exercise intolerance, malnutrition, bladder cancer, portal hypertension and CNS complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/5\">",
"     5",
"    </a>",
"    ]. Although most infections occur in residents of endemic areas, it has been clearly documented that brief freshwater exposure is sufficient to establish infection; thus, travelers may also be infected.",
"   </p>",
"   <p>",
"    Schistosomiasis species tend to occur in restricted geographic patterns as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      S. mansoni is most prevalent in certain tropical and subtropical areas of sub-Saharan Africa, the Middle East, South America and the Caribbean.",
"     </li>",
"     <li>",
"      S. haematobium infection is acquired predominantly in North Africa, sub-Saharan Africa, the Middle East, Turkey, and India.",
"     </li>",
"     <li>",
"      S. japonicum occurs only in Asia, particularly in China, the Philippines, Thailand, and Indonesia.",
"     </li>",
"     <li>",
"      S. intercalatum occurs only in central and West Africa",
"     </li>",
"     <li>",
"      S. mekongi is restricted to Laos and Cambodia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In endemic areas, the infection is usually acquired in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/6\">",
"     6",
"    </a>",
"    ]. The prevalence and intensity of infection rises with age and peaks at approximately 15 to 20 years. In older adults, the prevalence of infection does not change significantly, but the intensity (parasite burden) decreases dramatically [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, transmission tends to be higher in rural than urban areas [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/9\">",
"     9",
"    </a>",
"    ]. However, infections are not uniformly distributed within communities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/10\">",
"     10",
"    </a>",
"    ]; typically 5 to 10 percent of the community will be heavily infected, and the remainder will have mild to moderate infections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]. This uneven distribution may be partly related to proximity to freshwater since schistosomiasis is acquired via contact with the organism in a marine environment. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Life cycle'",
"    </a>",
"    below.) In one study from Uganda, the risk of infection was highest among those who lived near lakes or rivers; in contrast, almost no transmission occurred at altitudes &gt;1400 m or where total annual rainfall was &lt; 900 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Schistosomiasis is also an important consideration among refugees and travelers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/2,13,14\">",
"     2,13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14807?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment and prevention of schistosomiasis\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LIFE CYCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The life cycle of schistosomiasis is complex and requires both intermediate and definitive hosts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Transmission cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like all trematodes, schistosomes appear as unsegmented leaf-like organisms. The adult worms are approximately 1 to 2 cm in length with a cylindrical body, two terminal suckers, a blind digestive tract, and reproductive organs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/6\">",
"     6",
"    </a>",
"    ]. The male schistosome forms a groove or gynecophoric channel where the female resides.",
"   </p>",
"   <p>",
"    The females produce hundreds to thousands of eggs per day, depending on the species. After contact with water, each ovum releases a ciliated miracidium larva, which seeks an intermediate host, the snail. After four to six weeks, the miracida multiply asexually into sporocysts and later into cercarial larvae, which have a bifurcated tail. The cercaria leave the snail and seek a definitive host, where they develop into adult worms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Humans as the definitive host",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans acquire schistosomiasis via contact with freshwater containing infectious, free-living, cercarial larvae. Cercariae penetrate the intact skin of humans and, in the process, shed their forked tail to become schistosomulae. Schistosomulae migrate from the skin into the blood and lymph vessels and are carried to the heart and lungs. They then migrate through the pulmonary capillaries into the left side of the heart and, from there, into the arterial circulation. They are carried to the mesenteric arteries, splanchnic arteries, and portal veins, subsequently reaching the liver where they mature into adults over a period of one to four weeks.",
"   </p>",
"   <p>",
"    Different species have a propensity to affect different organs. The adult worms migrate against portal blood flow to varying destinations as listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mesenteric venules of the small intestine &mdash; S. japonicum and S. mekongi",
"     </li>",
"     <li>",
"      The mesenteric venules of the colon &mdash; S. mansoni and S. intercalatum",
"     </li>",
"     <li>",
"      The vesical venous plexus &mdash; S. haematobium",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The adults remain in these blood vessels for life, residing in permanent copulation and adhering to the wall of the blood vessels with suckers. These worms usually survive for five to seven years but can persist for up to 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like most helminths, adult schistosomes do not replicate within the host. After one to three months, the female worm begins to produce eggs, which can travel hematogenously to other sites or can traverse from the vascular space through host tissues to the lumen of the intestine or urinary bladder. The eggs are then variably excreted in the feces (S. mansoni, S. japonicum, S. haematobium, S. intercalatum, and S. mekongi) or the urine (S. haematobium).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Snails as the intermediate host",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excreted eggs each contain one male or female miracidium, which is an immature larval form. When eggs contact freshwater, the osmotic stress ruptures the shell, and the miracidia hatch and swim through water in search of a susceptible snail host. The miracidia then penetrate appropriate snail species and undergo asexual reproduction over a period of three to five weeks, developing into sporocysts, and then cercariae. Snails release thousands of cercariae into fresh water, each of which can penetrate skin if they come in contact with humans, thereby completing the life cycle. Cercariae can survive up to 48 hours in water but are most infectious to humans for the first few hours after release from the snail.",
"   </p>",
"   <p>",
"    Infection cannot be acquired by direct contact with excreta from an infected person, since parasite development in a snail is required. The different schistosomal species have different species of snails that serve as their intermediate hosts as listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      S. mansoni &mdash; Biomphalaria species",
"     </li>",
"     <li>",
"      S. haematobium &mdash; Bulinus species",
"     </li>",
"     <li>",
"      S. japonicum &mdash; Oncomelania species",
"     </li>",
"     <li>",
"      S. mekongi &mdash; Tricula species",
"     </li>",
"     <li>",
"      S. intercalatum &mdash; Bulinus species",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The snail preference contributes to the restricted geographic location of individual schistosome species.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pathology associated with adult worms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless adult worms migrate to an unusual location (such as the spinal cord or brain), adult worms do little damage to the host. They feed on circulating glucose and blood products, but usually do not cause symptoms.",
"   </p>",
"   <p>",
"    In animal models, no overt cellular inflammation is found around the mature parasite, whereas cellular infiltrate is consistently found around the eggs (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pathology associated with schistosomal eggs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eggs released into the bloodstream by adult worms can invade local tissues, where they release toxins and enzymes and provoke a TH-2-mediated immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/17\">",
"     17",
"    </a>",
"    ]. Inflammation and granuloma formation occurs around deposited eggs, which can lead to fibrosis and scarring of affected tissues, if the burden of eggs is heavy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    S. mansoni, S. japonicum, S, mekongi, and S. intercalatum eggs tend to either penetrate the bowel (adjacent to the mesenteric vessels in which the adult worms are residing) or travel via the portal venous system to the liver. In the bowel, granulomatous inflammation around the invading eggs can result in intestinal schistosomiasis characterized by ulceration and scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/19\">",
"     19",
"    </a>",
"    ]. In the liver, eggs lodge in the presinusoidal radicals of the portal vein, where they elicit a granulomatous fibrosing reaction that can eventually lead to blockade of venous blood flow. Secondary portal venous hypertension results, with compensatory portosystemic blood flow and progressive liver damage. The characteristic pathology seen within the liver is known as Symmers' pipestem fibrosis. This pathology is distinct from cirrhosis, since there is no hepatocyte dysfunction; instead, the portal hypertension results from fibrosis within blood vessels.",
"   </p>",
"   <p>",
"    The eggs of S. haematobium lead to granulomatous inflammation, ulceration of the vesical and ureteral walls with subsequent fibrosis. Functional bladder neck obstruction, hydroureter and hydronephrosis can ensue, as well as calcification of the urinary tract and bladder. These changes can eventually lead to renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34243?source=see_link\">",
"     \"Schistosomiasis and glomerular disease\"",
"    </a>",
"    .) Occasionally, S. haematobium infection is also associated with hepatic damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Parasite-host immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interaction between the parasite and host immune response is complex. Adult worms absorb host proteins and coat themselves with host antigens so that they can reside in the bloodstream for years without being attacked by the immune system. It is the host immune response to invading eggs that is the major cause of clinical disease. A host-mediated type 2 T-helper cell-induced (Th2) fibro-granulomatous inflammatory response occurs in reaction to the parasitic eggs, which may result in activation of hepatic stellate cells, the mediators of fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Immunity to infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunity to infection with any schistosome species is both innate and acquired. The factors leading to innate immunity are poorly understood, but host characteristics clearly contribute to heavy infections in some individuals and minimal burden in others. This susceptibility may be related to certain genetic characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the apparent invisibility that adult parasites have to the immune system, acquired immunity does develop. The prime evidence for this comes from examination of the age-intensity curve in endemic populations, which characteristically shows a rise in intensity of infection during the first two decades of life, followed by a decline in adults to very low levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/22\">",
"     22",
"    </a>",
"    ]. It has been estimated that adults acquire 1000 times fewer new infections than children in the same areas [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/23\">",
"     23",
"    </a>",
"    ]. Adults also develop immunity more quickly than children [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/24\">",
"     24",
"    </a>",
"    ]. There has also been considerable debate about the role behavioral factors (eg, walking barefoot and swimming) may play in the increased numbers of infections in children compared to adults [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients infected with schistosomes of all species are asymptomatic. The clinical picture in individuals presenting in nonendemic countries tends to be different from manifestations seen in the developing world because of differences in immunity to the parasite and in intensity of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Acute symptoms tend to be more common in nonimmune individuals, such as travelers, due to a more intense immune response to exposure. By contrast, chronic complications require a higher burden of infection and, thus, are mainly seen in individuals from endemic areas.",
"   </p>",
"   <p>",
"    Symptoms can be localized to specific organs or can be generalized, including fatigue. Symptoms can be divided into early and late stages of infection as discussed below. The different species of Schistosoma cause varying clinical complications, and different geographic strains within a species may have variable pathogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Acute infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute symptoms may present as swimmer's itch or Katayama fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Swimmer's itch",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial penetration of the skin by cercariae may be asymptomatic or may cause the characteristic \"swimmer's itch\". This is a localized dermatitis that can result in a pruritic papular or urticarial rash at the site of larval entry, which is typically on the lower legs or feet.",
"   </p>",
"   <p>",
"    When it occurs, swimmer's itch is usually seen within one day of exposure. Immediate tingling and itching at the site of entry may develop, followed by an intensely pruritic papular eruption 12 to 24 hours later, which can last more than a week [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/9\">",
"     9",
"    </a>",
"    ]. Prior sensitization to cercariae results in more rapid immune response and more severe symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This manifestation is most common with S. japonicum and occurs rarely with S. haematobium. Avian and mammalian schistosome species can also be a cause of swimmer's itch in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Katayama fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Katayama fever is a systemic hypersensitivity reaction against the migrating parasites, which occurs between two to eight weeks after exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/6,31\">",
"     6,31",
"    </a>",
"    ]. It is thought to be due to hypersensitivity to schistosome antigens and circulating immune complexes and coincides with the first two weeks of egg production, a time when the antigen burden grows dramatically. This acute manifestation is seen more frequently with S. mansoni or S. japonicum infections.",
"   </p>",
"   <p>",
"    Symptoms are also more likely to occur in travelers and other nonimmune hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/32\">",
"     32",
"    </a>",
"    ]. One study showed that acute symptoms occurred in 54 percent of a group of travelers to Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/33\">",
"     33",
"    </a>",
"    ]. Activities associated with acquisition include bathing and swimming in fresh water, scuba diving, water skiing, and rafting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms of Katayama fever include sudden onset of fever, chills, myalgias, arthralgias, dry cough, diarrhea and headache, often resembling serum sickness. Lymphadenopathy and hepatosplenomegaly may be prominent findings on physical examination. The symptoms usually resolve spontaneously over a period of a few weeks, but neck stiffness and coma can occur and occasional deaths have been reported related to intense infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients may develop eosinophilia and patchy infiltrates on chest x-ray [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/31\">",
"     31",
"    </a>",
"    ]. Some patients also develop persistent and more serious disease such as weight loss, dyspnea, and chronic diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of Katayama fever relies upon appropriate epidemiology for potential exposure and consistent clinical findings. The diagnosis can be complicated by the fact that eggs are rarely excreted in detectable amounts during this stage and antibody tests are usually negative. However, a peripheral eosinophilia will usually be present and often serves as an important clue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7398?source=see_link\">",
"     \"Diagnosis of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Chronic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic complications related to schistosomiasis are more common in endemic areas where individuals are at increased risk of a high burden of infection. As noted above, the severity of disease is related to the number of eggs trapped in tissues, their anatomic distribution, and the duration and intensity of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/9\">",
"     9",
"    </a>",
"    ]. Symptoms of chronic infection often begin insidiously but are frequently progressive without treatment, particularly with a high intensity of disease. The major manifestations vary according to the infecting species. The intensity of schistosomal infection is diagnosed with special quantification methods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7398?source=see_link\">",
"     \"Diagnosis of schistosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Intestinal schistosomiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal schistosomiasis is caused by S. mansoni, S. japonicum, S. intercalatum, S. mekongi and occasionally, S. haematobium infections. The most common symptoms include chronic or intermittent abdominal pain, poor appetite and diarrhea. Stools may be grossly bloody and chronic ulcerations may lead to secondary iron deficiency anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/35\">",
"     35",
"    </a>",
"    ]. Intestinal polyps can arise due to granulomatous inflammation surrounding eggs that are deposited in the bowel wall. Bowel ulcers and strictures can also develop. Rarely, an inflammatory mass can lead to obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/36\">",
"     36",
"    </a>",
"    ]; acute appendicitis has also been described in one case report [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hepatic schistosomiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver schistosomiasis occurs with S. mansoni, S. japonicum and S. mekongi infections. Infection can lead to two distinct syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammatory hepatic schistosomiasis is the main cause of hepatomegaly and severe splenomegaly in children and adolescents. The severity of disease is related to the intensity of the egg infestation.",
"     </li>",
"     <li>",
"      Chronic hepatic schistosomiasis develops years later in young and middle aged adults with a long duration of intense infection. Diffuse collage deposits in the periportal spaces leads to pathognomonic periportal or \"Symmer's pipestem fibrosis\" with accompanying splenomegaly and portal hypertension. However, hepatocellular function remains normal. Leading causes of morbidity and mortality include the formation of ascites and esophageal bleeding from varices.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Urinary schistosomiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary schistosomiasis is caused by S. haematobium infections. It may be asymptomatic or may cause microscopic or macroscopic hematuria, dysuria, and urinary frequency. Symptoms related to secondary anemia may be present. Blood is usually seen at the end of voiding (\"terminal hematuria\"), but in severe cases can be present throughout [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With progressive involvement, fibrosis and calcification of the bladder and ureters can occur resulting in hydroureter and hydronephrosis. Obstruction leading to kidney damage and secondary bacterial infections may also ensue; however, treatment usually results in improvement in anatomic abnormalities. In addition, chronic inflammation may lead to an increased risk of developing some forms of squamous cell carcinoma of the bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the direct invasion of the urinary system, infection with any schistosomal species can be associated with immune complex deposition in the kidneys, leading to proteinuria and the nephrotic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34243?source=see_link\">",
"     \"Schistosomiasis and glomerular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Neurologic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schistosomiasis can sometimes be associated with serious neurologic complications. The two main clinical syndromes are spinal cord neuroschistosomiasis (acute or subacute myelopathy) and localized cerebral or cerebellar neuroschistosomiasis (focal CNS impairment, seizures, increased intracranial pressure) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurologic complications can occur even in individuals who are lightly infected; prevention of this complication is one of the main reasons that infected but asymptomatic travelers should be treated.",
"   </p>",
"   <p>",
"    These complications result in one to two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eggs may enter the vertebral venous plexus and then embolize to the spinal cord or brain, resulting in granulomas at these sites.",
"     </li>",
"     <li>",
"      Adult worms may migrate aberrantly to the spinal cord or brain.",
"     </li>",
"     <li>",
"      Transverse myelitis &mdash; S. mansoni and S. haematobium infections typically involve the spinal cord, leading to transverse myelitis. One review of neurologic disease in schistosomiasis suggested that the time between exposure and the onset of neurologic symptoms ranges from 38 days to 6 years, but in endemic areas, the time of exposure often cannot be determined [",
"      <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/42\">",
"       42",
"      </a>",
"      ]. Patients usually present with rapidly progressing symptoms of myelitis, including lower limb pain, weakness and bowel dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/43\">",
"       43",
"      </a>",
"      ]. In one review, the thoracolumbar region of the spinal cord was most frequently involved (&gt;75 percent of cases) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/44\">",
"       44",
"      </a>",
"      ]. Spinal cord involvement can lead to permanent paralysis and brain involvement can be fatal.",
"     </li>",
"     <li>",
"      CNS schistosomiasis &mdash; CNS schistosomiasis can present several years after exposure, and has been described more commonly with S. japonicum [",
"      <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/45\">",
"       45",
"      </a>",
"      ]. Infection can result in increased intracranial pressure and the development of epilepsy or focal neurologic symptoms. One report suggested that epilepsy develops in one to two percent of individuals with S. japonicum infection, but this is difficult to estimate since many infections remain asymptomatic and undiagnosed [",
"      <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Pulmonary complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary manifestations of infection can also be seen, particularly in people with hepatosplenic disease due to heavy infections with S. mansoni, S. japonicum or S. haematobium infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Presinusoidal portal hypertension fosters the development of portosystemic collateral vessels that allow schistosome eggs to embolize into the pulmonary circulation. Eggs lodge in pulmonary arterioles of 50 to 100 micrometer diameter and produce a granulomatous pulmonary endarteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/49\">",
"     49",
"    </a>",
"    ]. Pulmonary hypertension and cor pulmonale gradually ensue.",
"   </p>",
"   <p>",
"    Dyspnea is the principal symptom attributable to this pulmonary process [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/50\">",
"     50",
"    </a>",
"    ]. The chest x-ray initially shows fine miliary nodules. Echocardiography is useful screening tool for pulmonary hypertension in patients with hepatosplenic schistosomiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/51\">",
"     51",
"    </a>",
"    ]. As the disease evolves, the heart enlarges and the pulmonary arteries dilate to aneurysmal proportions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/50\">",
"     50",
"    </a>",
"    ]. These pulmonary changes represent end-stage alterations and are often irreversible.",
"   </p>",
"   <p>",
"    In addition, initiation of antischistosomal therapy for established infections may result in embolization of adult worms to the lungs, resulting in coughing and wheezing, accompanied by new infiltrates on chest x-ray [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/52\">",
"     52",
"    </a>",
"    ]. These changes are self-limited and do not necessitate cessation of antischistosomal therapy. The mechanism probably involves an immunologic response to exposed or released antigens from dead worms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Genitourinary involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genital involvement can also occur, especially with S. haematobium [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/54\">",
"     54",
"    </a>",
"    ]. Symptoms in female patients include hypertrophic and ulcerative lesions of the vulva, vagina, and cervix [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/6,55\">",
"     6,55",
"    </a>",
"    ]. Involvement on the ovaries or fallopian tubes can lead to infertility. In men, the epididymis, testicles, spermatic chord or prostate can be involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29787230\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant associations have also been noted between schistosome infection and anemia, nutritional status, growth retardation and general disability [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     INTERACTION WITH OTHER INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are important implications of schistosomiasis relative to other common infections:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Recurrent bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent bacteremia is associated with schistosomiasis infection via two proposed mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enteric bacteria can enter the bloodstream from areas of inflamed colonic mucosa that have been damaged by egg passage [",
"      <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adult schistosomes can also ingest bacteria and serve as a reservoir for infections [",
"      <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recurrent urinary tract infections or bacteremia due to Salmonella are classic complications of schistosomiasis, but infection with any bacterial organism can occur. Eradication of the adult worms is recommended to prevent further relapses of bacterial infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been postulated that infection with schistosoma haematobium may increase the risk of HIV infection analogous to the presence of other sexually transmitted diseases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      S. haematobium egg excretion in semen is associated with the presence of inflammatory cells in infected men [",
"      <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Egg-induced inflammatory lesions in the lining of the lower reproductive tract in women are associated with an increased risk of HIV transmission [",
"      <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/58,59\">",
"       58,59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Schistosome infections may render the host more susceptible to HIV infection by interfering with host immune responses [",
"      <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/60,61\">",
"       60,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Concomitant schistosomiasis infection may also be a contributing factor for increased HIV replication and cytokine dysregulation in patients who are HIV-seropositive [",
"      <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the relationship between schistosomiasis and HIV infection is unclear and conflicting evidence disputing faster progression of HIV disease in those coinfected with schistosomiasis has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/63\">",
"     63",
"    </a>",
"    ]. It has also been suggested that HIV infection may effect immune responses and eosinophil expression, resulting in increased susceptibility to reinfection with schistosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Symptomatic schistosomiasis has also been described as an immune restoration syndrome in a patient receiving antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Hepatitis B virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant interactions between schistosomiasis caused by S. mansoni or S. japonicum and hepatitis B have been reported. People with coinfections have more severe disease and a worse prognosis than those infected with either pathogen alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Hepatitis C virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The origin of the hepatitis C epidemic in Egypt has been attributed to the use of intravenous tartar emetic that was administered in the early 1950s to 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Persons who have coinfection with schistosomiasis and hepatitis C appear to have more severe liver disease than those with HCV alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/69\">",
"     69",
"    </a>",
"    ]. This may be related to alteration of cellular immune responses to HCV antigens that is modulated by schistosomial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/70\">",
"     70",
"    </a>",
"    ]. This leads to an increase in HCV RNA, increased risk of chronicity, and more rapid progression of liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria and schistosomiasis are coendemic in many areas, and studies have shown coinfection with malaria may increase the level of morbidity in hepatosplenic schistosomiasis, and alter the host immune response towards schistosome antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/60,72\">",
"     60,72",
"    </a>",
"    ]. Potentiation for the development of hepatocellular carcinoma in coinfected individuals may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, one study of Malian children, demonstrated that children from ages four to eight years with asymptomatic urinary schistosomiasis infection had a delayed onset to their first clinical malaria infection, fewer malarial episodes, and a lower mean parasite density at initial infection compared to children who did not have S. haematobium infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/74\">",
"     74",
"    </a>",
"    ]. This protective effect was not seen in older children 9 to 14 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SCHISTOSOMIASIS AND PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although schistosomes infect approximately 40 million women of child-bearing age, there are few data on potential related morbidity of this parasitic infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One cross-sectional survey of 972 pregnant women in Tanzania demonstrated that heavy infection with S. mansoni was associated with an increased risk of anemia after controlling for potential confounders [",
"      <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two observational studies indicate a possible association between schistosomal infection and low birth weight, although methodologic flaws and small study size limit interpretation of both studies [",
"      <a class=\"abstract\" href=\"UTD.htm?15/38/15977/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since maternal health is linked to gestational outcomes, schistosomiasis may potentially impact fetal health through its detrimental effects on the hematologic and nutritional status of the mother.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Schistosomiasis can be associated with serious morbidity and mortality. Chronic complications are generally seen in those with a high parasite load, which usually occurs in individuals who live in endemic areas and have recurrent exposure. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three major schistosomal species include S. mansoni and S. japonicum (which are associated with intestinal and hepatic complications) and S. haematobium (urinary tract disease). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Schistosome species'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is estimated that more than 200 million people worldwide have schistosomiasis and that the infection is responsible for more than 200,000 deaths annually. The distribution of the different schistosomal species varies by geography (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Humans acquire schistosomiasis via contact with freshwater containing infectious, free-living, cercarial larvae (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Life cycle'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The pathogenesis of schistosomiasis is related to the host immune response to the eggs that invade local tissues. Inflammation and granuloma formation occurs around deposited eggs, which can lead to fibrosis and scarring of affected tissues (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathogenesis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The majority of individuals infected with schistosomes of all species are asymptomatic. The clinical picture in individuals presenting in nonendemic countries tends to be different from manifestations seen in the developing world because of differences in immunity to the parasite and in intensity of infection. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of acute schistoma infection include swimmer's itch (a localized dermatitis) or Katayama fever (a hypersensitivity reaction marked by fever and cough). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Swimmer's itch'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Katayama fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major manifestations of chronic disease vary according to the infecting species and include intestinal, hepatic, urinary, neurologic, and pulmonary disease. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Chronic infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are important implications of schistosomiasis relative to other common infections such as HIV, hepatitis B, hepatitis C, or malaria. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Interaction with other infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two observational studies indicate a possible association between schistosomal infection and low birth weight. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Schistosomiasis and pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/1\">",
"      Blanchard TJ. Schistosomiasis. Travel Med Infect Dis 2004; 2:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/2\">",
"      Whitty CJ, Mabey DC, Armstrong M, et al. Presentation and outcome of 1107 cases of schistosomiasis from Africa diagnosed in a non-endemic country. Trans R Soc Trop Med Hyg 2000; 94:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/3\">",
"      Chistulo, L, Loverde, P, Engels, D. Disease Watch: Schistosomiasis. TDR Nature Reviews Microbiology 2004; 2:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/4\">",
"      Elliott DE. Schistosomiasis. Pathophysiology, diagnosis, and treatment. Gastroenterol Clin North Am 1996; 25:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/5\">",
"      King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 2005; 365:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/6\">",
"      Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006; 368:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/7\">",
"      Hagan P, Gryseels B. Schistosomiasis research and the European Community. Trop Geogr Med 1994; 46:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/8\">",
"      King CH, Keating CE, Muruka JF, et al. Urinary tract morbidity in schistosomiasis haematobia: associations with age and intensity of infection in an endemic area of Coast Province, Kenya. Am J Trop Med Hyg 1988; 39:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/9\">",
"      Lucey DR, Maguire JH. Schistosomiasis. Infect Dis Clin North Am 1993; 7:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/10\">",
"      Clements AC, Moyeed R, Brooker S. Bayesian geostatistical prediction of the intensity of infection with Schistosoma mansoni in East Africa. Parasitology 2006; 133:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/11\">",
"      Anderson, R. Determinants of infection in human schistosomiasis. Baillere's Clinical Tropical Medicine and Communicable Diseases 1987; 2:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/12\">",
"      Kabatereine NB, Brooker S, Tukahebwa EM, et al. Epidemiology and geography of Schistosoma mansoni in Uganda: implications for planning control. Trop Med Int Health 2004; 9:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/13\">",
"      Posey DL, Blackburn BG, Weinberg M, et al. High prevalence and presumptive treatment of schistosomiasis and strongyloidiasis among African refugees. Clin Infect Dis 2007; 45:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/14\">",
"      Meltzer E, Artom G, Marva E, et al. Schistosomiasis among travelers: new aspects of an old disease. Emerg Infect Dis 2006; 12:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/15\">",
"      Arnon R. Life span of parasite in schistosomiasis patients. Isr J Med Sci 1990; 26:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/16\">",
"      Keating JH, Wilson RA, Skelly PJ. No overt cellular inflammation around intravascular schistosomes in vivo. J Parasitol 2006; 92:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/17\">",
"      Coutinho HM, Acosta LP, Wu HW, et al. Th2 cytokines are associated with persistent hepatic fibrosis in human Schistosoma japonicum infection. J Infect Dis 2007; 195:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/18\">",
"      Cheever AW, Hoffmann KF, Wynn TA. Immunopathology of schistosomiasis mansoni in mice and men. Immunol Today 2000; 21:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/19\">",
"      Strickland GT. Gastrointestinal manifestations of schistosomiasis. Gut 1994; 35:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/20\">",
"      Bartley PB, Ramm GA, Jones MK, et al. A contributory role for activated hepatic stellate cells in the dynamics of Schistosoma japonicum egg-induced fibrosis. Int J Parasitol 2006; 36:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/21\">",
"      Abel L, Demenais F, Prata A, et al. Evidence for the segregation of a major gene in human susceptibility/resistance to infection by Schistosoma mansoni. Am J Hum Genet 1991; 48:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/22\">",
"      Butterworth AE. Immunological aspects of human schistosomiasis. Br Med Bull 1998; 54:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/23\">",
"      Wilkins HA, Goll PH, Marshall TF, Moore PJ. Dynamics of Schistosoma haematobium infection in a Gambian community. III. Acquisition and loss of infection. Trans R Soc Trop Med Hyg 1984; 78:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/24\">",
"      Gryseels B, Stelma F, Talla I, et al. Immuno-epidemiology of Schistosoma mansoni infections in a recently exposed community in Senegal. Mem Inst Oswaldo Cruz 1995; 90:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/25\">",
"      Sleigh, A, Mott, KJ. Schistosomiasis. Clinics in Tropical Medicine and Communicable Diseases 1986; 1:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/26\">",
"      Corachan M. Schistosomiasis and international travel. Clin Infect Dis 2002; 35:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/27\">",
"      Grobusch MP, M&uuml;hlberger N, Jelinek T, et al. Imported schistosomiasis in Europe: sentinel surveillance data from TropNetEurop. J Travel Med 2003; 10:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/28\">",
"      Boggild AK, Yohanna S, Keystone JS, Kain KC. Prospective analysis of parasitic infections in Canadian travelers and immigrants. J Travel Med 2006; 13:138.",
"     </a>",
"    </li>",
"    <li>",
"     King, C, Mahmouud, AA. Schistosomiasis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, vol 2, Guerrant R, Walker, DH, Weller, PF, (Eds) Churchill Livingstone, Philadelphia 1999. p.1031.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/30\">",
"      Hoeffler DF. Cercarial dermatitis. Arch Environ Health 1974; 29:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/31\">",
"      Ross AG, Vickers D, Olds GR, et al. Katayama syndrome. Lancet Infect Dis 2007; 7:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/32\">",
"      Bottieau E, Clerinx J, de Vega MR, et al. Imported Katayama fever: clinical and biological features at presentation and during treatment. J Infect 2006; 52:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/33\">",
"      Visser LG, Polderman AM, Stuiver PC. Outbreak of schistosomiasis among travelers returning from Mali, West Africa. Clin Infect Dis 1995; 20:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/34\">",
"      Jelinek T, Nothdurft HD, L&ouml;scher T. Risk Factors for Typhoid Fever in Travelers. J Travel Med 1996; 3:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/35\">",
"      Stephenson L. The impact of schistosomiasis on human nutrition. Parasitology 1993; 107 Suppl:S107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/36\">",
"      Lamyman MJ, Noble DJ, Narang S, Dehalvi N. Small bowel obstruction secondary to intestinal schistosomiasis. Trans R Soc Trop Med Hyg 2006; 100:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/37\">",
"      Gabbi C, Bertolotti M, Iori R, et al. Acute abdomen associated with schistosomiasis of the appendix. Dig Dis Sci 2006; 51:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/38\">",
"      Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med 2002; 346:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/39\">",
"      Andrade ZA, Rocha H. Schistosomal glomerulopathy. Kidney Int 1979; 16:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/40\">",
"      Nascimento-Carvalho CM, Moreno-Carvalho OA. Neuroschistosomiasis due to Schistosoma mansoni: a review of pathogenesis, clinical syndromes and diagnostic approaches. Rev Inst Med Trop Sao Paulo 2005; 47:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/41\">",
"      Kim AH, Maher CO, Smith ER. Lumbar intramedullary spinal schistosomiasis presenting as progressive paraparesis: case report. Neurosurgery 2006; 58:E996; discussion E996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/42\">",
"      Scrimgeour EM, Gajdusek DC. Involvement of the central nervous system in Schistosoma mansoni and S. haematobium infection. A review. Brain 1985; 108 ( Pt 4):1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/43\">",
"      Ferrari TC. Involvement of central nervous system in the schistosomiasis. Mem Inst Oswaldo Cruz 2004; 99:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/44\">",
"      Ferrari TC. Spinal cord schistosomiasis. A report of 2 cases and review emphasizing clinical aspects. Medicine (Baltimore) 1999; 78:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/45\">",
"      Amorosa V, Kremens D, Wolfe MS, et al. Schistosoma mansoni in family 5 years after safari. Emerg Infect Dis 2005; 11:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/46\">",
"      Pittella JE. Neuroschistosomiasis. Brain Pathol 1997; 7:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/47\">",
"      Sarwat AK, Tag el Din MA, Bassiouni M, Ashmawi SS. Schistosomiasis of the lung. J Egypt Soc Parasitol 1986; 16:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/48\">",
"      Da Silva LC, Carrilho FJ. Hepatosplenic schistosomiasis. Pathophysiology and treatment. Gastroenterol Clin North Am 1992; 21:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/49\">",
"      Andrade ZA, Andrade SG. Pathogenesis of schistosomal pulmonary arteritis. Am J Trop Med Hyg 1970; 19:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/50\">",
"      FARID Z, GREER JW, ISHAK KG, et al. Chronic pulmonary schistosomiasis. Am Rev Tuberc 1959; 79:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/51\">",
"      Lapa M, Dias B, Jardim C, et al. Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation 2009; 119:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/52\">",
"      Pedroso ER, Lambertucci JR, Greco DB, et al. Pulmonary schistosomiasis mansoni: post-treatment pulmonary clinical-radiological alterations in patients in the chronic phase: a double-blind study. Trans R Soc Trop Med Hyg 1987; 81:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/53\">",
"      Ottesen EA, Weller PF. Eosinophilia following treatment of patients with schistosomiasis mansoni and Bancroft's filariasis. J Infect Dis 1979; 139:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/54\">",
"      Kjetland EF, Mduluza T, Ndhlovu PD, et al. Genital schistosomiasis in women: a clinical 12-month in vivo study following treatment with praziquantel. Trans R Soc Trop Med Hyg 2006; 100:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/55\">",
"      Chen W, Flynn EA, Shreefter MJ, Blagg NA. Schistosomiasis: an unusual finding of the cervix. Obstet Gynecol 2012; 119:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/56\">",
"      Rocha H, Kirk JW, Hearey CD Jr. Prolonged Salmonella bacteremia in patients with Schistosoma mansoni infection. Arch Intern Med 1971; 128:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/57\">",
"      Leutscher PD, Pedersen M, Raharisolo C, et al. Increased prevalence of leukocytes and elevated cytokine levels in semen from Schistosoma haematobium-infected individuals. J Infect Dis 2005; 191:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/58\">",
"      Feldmeier H, Krantz I, Poggensee G. Female genital schistosomiasis as a risk-factor for the transmission of HIV. Int J STD AIDS 1994; 5:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/59\">",
"      Poggensee G, Feldmeier H. Female genital schistosomiasis: facts and hypotheses. Acta Trop 2001; 79:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/60\">",
"      Vennervald BJ, Dunne DW. Morbidity in schistosomiasis: an update. Curr Opin Infect Dis 2004; 17:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/61\">",
"      Kjetland EF, Ndhlovu PD, Gomo E, et al. Association between genital schistosomiasis and HIV in rural Zimbabwean women. AIDS 2006; 20:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/62\">",
"      Kallestrup P, Zinyama R, Gomo E, et al. Schistosomiasis and HIV-1 infection in rural Zimbabwe: effect of treatment of schistosomiasis on CD4 cell count and plasma HIV-1 RNA load. J Infect Dis 2005; 192:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/63\">",
"      Brown M, Kizza M, Watera C, et al. Helminth infection is not associated with faster progression of HIV disease in coinfected adults in Uganda. J Infect Dis 2004; 190:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/64\">",
"      Joseph S, Jones FM, Laidlaw ME, et al. Impairment of the Schistosoma mansoni-specific immune responses elicited by treatment with praziquantel in Ugandans with HIV-1 coinfection. J Infect Dis 2004; 190:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/65\">",
"      Ganley-Leal LM, Mwinzi PN, Cetre-Sossah CB, et al. Correlation between eosinophils and protection against reinfection with Schistosoma mansoni and the effect of human immunodeficiency virus type 1 coinfection in humans. Infect Immun 2006; 74:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/66\">",
"      de Silva S, Walsh J, Brown M. Symptomatic Schistosoma mansoni infection as an immune restoration phenomenon in a patient receiving antiretroviral therapy. Clin Infect Dis 2006; 42:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/67\">",
"      Lambertucci JR, Rayes AA, Serufo JC, et al. Schistosomiasis and associated infections. Mem Inst Oswaldo Cruz 1998; 93 Suppl 1:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/68\">",
"      Mohamed MK, Bakr I, El-Hoseiny M, et al. HCV-related morbidity in a rural community of Egypt. J Med Virol 2006; 78:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/69\">",
"      Strickland GT. Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology 2006; 43:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/70\">",
"      Farid A, Al-Sherbiny M, Osman A, et al. Schistosoma infection inhibits cellular immune responses to core HCV peptides. Parasite Immunol 2005; 27:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/71\">",
"      Kamal SM, Turner B, He Q, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 2006; 43:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/72\">",
"      Pierrot C, Wilson S, Lallet H, et al. Identification of a novel antigen of Schistosoma mansoni shared with Plasmodium falciparum and evaluation of different cross-reactive antibody subclasses induced by human schistosomiasis and malaria. Infect Immun 2006; 74:3347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/73\">",
"      Yosry A. Schistosomiasis and neoplasia. Contrib Microbiol 2006; 13:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/74\">",
"      Lyke KE, Dicko A, Dabo A, et al. Association of Schistosoma haematobium infection with protection against acute Plasmodium falciparum malaria in Malian children. Am J Trop Med Hyg 2005; 73:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/75\">",
"      Ajanga A, Lwambo NJ, Blair L, et al. Schistosoma mansoni in pregnancy and associations with anaemia in northwest Tanzania. Trans R Soc Trop Med Hyg 2006; 100:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/38/15977/abstract/76\">",
"      Friedman JF, Mital P, Kanzaria HK, et al. Schistosomiasis and pregnancy. Trends Parasitol 2007; 23:159.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5717 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.97.94.19-F6CCE2A0D3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_38_15977=[""].join("\n");
var outline_f15_38_15977=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCHISTOSOME SPECIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LIFE CYCLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Transmission cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Humans as the definitive host",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Snails as the intermediate host",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pathology associated with adult worms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pathology associated with schistosomal eggs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Parasite-host immune response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Immunity to infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Acute infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Swimmer's itch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Katayama fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Chronic infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Intestinal schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hepatic schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Urinary schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Neurologic complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Genitourinary involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29787230\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      INTERACTION WITH OTHER INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Recurrent bacteremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Hepatitis B virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SCHISTOSOMIASIS AND PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7398?source=related_link\">",
"      Diagnosis of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34243?source=related_link\">",
"      Schistosomiasis and glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14807?source=related_link\">",
"      Treatment and prevention of schistosomiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_38_15978="Ibuprofen: Drug information";
var content_f15_38_15978=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ibuprofen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"    see \"Ibuprofen: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"    see \"Ibuprofen: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Addaprin [OTC];",
"     </li>",
"     <li>",
"      Advil&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Advil&reg; Infants' [OTC];",
"     </li>",
"     <li>",
"      Advil&reg; Migraine [OTC];",
"     </li>",
"     <li>",
"      Advil&reg; [OTC];",
"     </li>",
"     <li>",
"      Caldolor&reg;;",
"     </li>",
"     <li>",
"      I-Prin [OTC];",
"     </li>",
"     <li>",
"      Ibu-200 [OTC];",
"     </li>",
"     <li>",
"      Ibu&reg;;",
"     </li>",
"     <li>",
"      Midol&reg; Cramps &amp; Body Aches [OTC];",
"     </li>",
"     <li>",
"      Motrin&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Motrin&reg; IB [OTC];",
"     </li>",
"     <li>",
"      Motrin&reg; Infants' [OTC];",
"     </li>",
"     <li>",
"      Motrin&reg; Junior [OTC];",
"     </li>",
"     <li>",
"      NeoProfen&reg;;",
"     </li>",
"     <li>",
"      Proprinal&reg; [OTC];",
"     </li>",
"     <li>",
"      TopCare&reg; Junior Strength [OTC];",
"     </li>",
"     <li>",
"      Ultraprin [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F181457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Advil&reg;;",
"     </li>",
"     <li>",
"      Advil&reg; Children's;",
"     </li>",
"     <li>",
"      Apo-Ibuprofen&reg;;",
"     </li>",
"     <li>",
"      Motrin&reg; (Children's);",
"     </li>",
"     <li>",
"      Motrin&reg; IB;",
"     </li>",
"     <li>",
"      Novo-Profen;",
"     </li>",
"     <li>",
"      Nu-Ibuprofen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F181507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral;",
"     </li>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F181461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inflammatory disease:",
"     </b>",
"     Oral: 400-800 mg/dose 3-4 times/day (maximum: 3.2 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Analgesia/pain/fever/dysmenorrhea:",
"     </b>",
"     Oral: 200-400 mg/dose every 4-6 hours (maximum daily dose: 1.2 g, unless directed by physician; under physician supervision daily doses &le;2.4 g may be used)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Analgesic:",
"     </b>",
"     I.V. (Caldolor&reg;): 400-800 mg every 6 hours as needed (maximum: 3.2 g/day).",
"     <b>",
"      Note",
"     </b>",
"     : Patients should be well hydrated prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antipyretic:",
"     </b>",
"     I.V. (Caldolor&reg;): Initial: 400 mg, then every 4-6 hours or 100-200 mg every 4 hours as needed (maximum: 3.2 g/day).",
"     <b>",
"      Note",
"     </b>",
"     : Patients should be well hydrated prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      OTC labeling (analgesic, antipyretic):",
"     </i>",
"     Oral: 200 mg every 4-6 hours as needed (maximum: 1200 mg/24 hours); treatment for &gt;10 days is not recommended unless directed by healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Migraine: 2 capsules at onset of symptoms (maximum: 400 mg/24 hours unless directed by healthcare provider)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F181483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"      see \"Ibuprofen: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antipyretic:",
"     </b>",
"     Oral: 6 months to 12 years: Temperature &lt;102.5&deg;F (39&deg;C): 5 mg/kg/dose; temperature &gt;102.5&deg;F: 10 mg/kg/dose given every 6-8 hours; maximum daily dose: 40 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Juvenile idiopathic arthritis (JIA):",
"     </b>",
"     Oral: 30-50 mg/kg/24 hours divided every 8 hours; start at lower end of dosing range and titrate upward (maximum: 2.4 g/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Analgesic:",
"     </b>",
"     Oral: 4-10 mg/kg/dose every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cystic fibrosis (unlabeled use):",
"     </b>",
"     Oral: Chronic (&gt;4 years) twice daily dosing adjusted to maintain serum concentration of 50-100 mcg/mL has been associated with slowing of disease progression in younger patients with mild lung disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patent ductus arteriosus",
"     </b>",
"     : I.V. (ibuprofen lysine [NeoProfen&reg;]): Infants between 500-1500 g and &le;32 weeks GA: Initial dose: Ibuprofen 10 mg/kg, followed by two doses of 5 mg/kg at 24 and 48 hours. Dose should be based on birth weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      OTC labeling (analgesic, antipyretic):",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Treatment for &gt;10 days is not recommended unless directed by healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children 6 months to 11 years:",
"     </i>",
"     See table; use of weight to select dose is preferred; doses may be repeated every 6-8 hours (maximum: 4 doses/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &ge;12 years:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Ibuprofen Dosing",
"     </caption>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Weight",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (lb)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dosage",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12-17",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6-11 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         18-23",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12-23 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         24-35",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         36-47",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4-5 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         48-59",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6-8 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60-71",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9-10 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         72-95",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         300",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F181462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6784600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If anuria or oliguria evident, hold dose until renal function returns to normal.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F181463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F181430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg;: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; IB: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Junior: 100 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid filled, oral: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg;: 200 mg [contains potassium 20 mg/capsule; solubilized ibuprofen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg; Migraine: 200 mg [contains potassium 20 mg/capsule; solubilized ibuprofen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 200 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gelcap, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg;: 200 mg [contains coconut oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caldolor&reg;: 100 mg/mL (4 mL, 8 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as lysine [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NeoProfen&reg;: 17.1 mg/mL (2 mL) [equivalent to ibuprofen base 10 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 100 mg/5 mL (5 mL, 10 mL, 120 mL, 240 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg; Children's: 100 mg/5 mL (120 mL) [contains propylene glycol, sodium 10 mg/5 mL, sodium benzoate; blue raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg; Children's: 100 mg/5 mL (120 mL) [contains propylene glycol, sodium 3 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg; Children's: 100 mg/5 mL (120 mL) [contains sodium 3 mg/5 mL, sodium benzoate; fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Children's: 100 mg/5 mL (120 mL) [dye free, ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Children's: 100 mg/5 mL (60 mL, 120 mL) [ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Children's: 100 mg/5 mL (120 mL) [ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Children's: 100 mg/5 mL (120 mL) [ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Children's: 100 mg/5 mL (120 mL) [ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; tropical punch flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral [concentrate/drops]: 40 mg/mL (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg; Infants': 40 mg/mL (15 mL) [contains sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg; Infants': 40 mg/mL (15 mL) [dye free; contains propylene glycol, sodium benzoate; white grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Infants': 40 mg/mL (15 mL) [dye free, ethanol free; contains sodium benzoate; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Infants': 40 mg/mL (15 mL) [ethanol free; contains sodium benzoate; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg, 400 mg, 600 mg, 800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Addaprin: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Advil&reg;: 200 mg [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I-Prin: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ibu-200: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ibu&reg;: 400 mg, 600 mg, 800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Midol&reg; Cramps &amp; Body Aches: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; IB: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proprinal&reg;: 200 mg [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultraprin: 200 mg [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Junior: 100 mg [contains phenylalanine 2.8 mg/tablet; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Motrin&reg; Junior: 100 mg [contains phenylalanine 2.8 mg/tablet; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TopCare&reg; Junior Strength: 100 mg [scored; orange flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F181416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Caplet, liquid-filled capsule, softgel capsule, suspension, tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088647.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088647.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F181435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caldolor&reg;: For I.V. administration only; infuse over at least 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NeoProfen&reg; (ibuprofen lysine): For I.V. administration only; administration via umbilical arterial line has not been evaluated. Infuse over 15 minutes through port closest to insertion site. Avoid extravasation. Do not administer simultaneously via same line with TPN. If needed, interrupt TPN for 15 minutes prior to and after ibuprofen administration, keeping line open with dextrose or saline.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2985823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibuprofen injection (Caldolor&reg;): Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibuprofen lysine injection (NeoProfen&reg;): Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with TPN solution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F181434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Inflammatory diseases and rheumatoid disorders including juvenile idiopathic arthritis (JIA), mild-to-moderate pain, fever, dysmenorrhea, osteoarthritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ibuprofen injection (Caldolor&reg;): Management of mild-to-moderate pain; management moderate-to-severe pain when used concurrently with an opioid analgesic; reduction of fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ibuprofen lysine injection (NeoProfen&reg;): To induce closure of a clinically-significant patent ductus arteriosus (PDA) in premature infants weighing between 500-1500 g and who are &le;32 weeks gestational age (GA)  when usual treatments are ineffective",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F181503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cystic fibrosis, gout, ankylosing spondylitis, acute migraine headache, migraine prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F181516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Haltran&reg; may be confused with Halfprin&reg;",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Motrin&reg; may be confused with Neurontin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Injectable formulations: Both ibuprofen and ibuprofen lysine are available for parenteral use. Ibuprofen lysine is",
"       <b>",
"        only",
"       </b>",
"       indicated for closure of a clinically-significant patent ductus arteriosus.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F181505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (3% to 9%), headache (1% to 3%), nervousness (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (3% to 9%), itching (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid retention (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Epigastric pain (3% to 9%), heartburn (3% to 9%), nausea (3% to 9%), abdominal pain/cramps/distress (1% to 3%), appetite decreased (1% to 3%), constipation (1% to 3%), diarrhea (1% to 3%), dyspepsia (1% to 3%), flatulence (1% to 3%), vomiting (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (3% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, agranulocytosis, anaphylaxis, aplastic anemia, azotemia, blurred vision, bone marrow suppression, confusion, creatinine clearance decreased, duodenal ulcer, edema, eosinophilia, epistaxis, erythema multiforme, gastric ulcer, GI bleed, GI hemorrhage, GI ulceration, hallucinations, hearing decreased, hematuria, hematocrit decreased, hemoglobin decreased, hemolytic anemia, hepatitis, hypertension, inhibition of platelet aggregation, jaundice, liver function tests abnormal, leukopenia, melena, neutropenia, pancreatitis, photosensitivity, Stevens-Johnson syndrome, thrombocytopenia, toxic amblyopia, toxic epidermal necrolysis, urticaria, vesiculobullous eruptions, vision changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Injection: Ibuprofen (Caldolor&reg;):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Edema, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypernatremia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, dyspepsia, flatulence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia, hemorrhage, neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Renal: BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Cough",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Injection: Ibuprofen lysine (NeoProfen&reg;):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Intraventricular hemorrhage (29%; grade 3/4: 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Skin irritation (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia (12%), hypoglycemia (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: GI disorders, non NEC (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia (32%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Apnea (28%), respiratory infection (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Sepsis (43%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenal insufficiency (7%), hypernatremia (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Urea increased (7%), renal impairment (6%), creatinine increased (3%), urine output decreased (3%; small decrease reported on days 2-6 with compensatory increase in output on day 9), renal failure (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory failure (10%), atelectasis (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined:  Abdominal distension, cholestasis, feeding problems, gastritis, GI reflux, heart failure, hyperglycemia, hypotension, ileus, infection, inguinal hernia, injection site reaction, jaundice, neutropenia, seizure, tachycardia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: GI perforation, necrotizing enterocolitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F181438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ibuprofen; history of asthma, urticaria, or allergic-type reaction to aspirin or other NSAIDs; aspirin triad (eg, bronchial asthma, aspirin intolerance, rhinitis); perioperative pain in the setting of coronary artery bypass graft (CABG) surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Ibuprofen lysine (NeoProfen&reg;): Preterm infants with untreated proven or suspected infection; congenital heart disease where patency of the PDA is necessary for pulmonary or systemic blood flow; bleeding (especially with active intracranial hemorrhage or GI bleed); thrombocytopenia; coagulation defects; proven or suspected necrotizing enterocolitis (NEC); significant renal dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F181420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including fatal MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long-term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events can be fatal and may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of ethanol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic events: Blurred/diminished vision, scotomata, and changes in color vision have been reported. Discontinue therapy and refer for ophthalmologic evaluation if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension. Response to ACE inhibitors, thiazides, or loop diuretics may be impaired with concurrent use of NSAIDs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid chronic use (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent); nonselective oral NSAID use is associated with an increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, &gt;75 years or age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents) (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ibuprofen injection (Caldolor&reg;): Must be diluted prior to administration; hemolysis can occur if not diluted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ibuprofen lysine injection (NeoProfen&reg;): Hold second or third doses if urinary output is &lt;0.6 mL/kg/hour. May alter signs of infection. May inhibit platelet aggregation; monitor for signs of bleeding. May displace bilirubin; use caution when total bilirubin is elevated. Long-term evaluations of neurodevelopment, growth, or diseases associated with prematurity following treatment have not been conducted. A second course of treatment, alternative pharmacologic therapy or surgery may be needed if the ductus arteriosus fails to close or reopens following the initial course of therapy. Avoid extravasation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self medication (OTC use): Prior to self-medication, patients should contact healthcare provider if they have had recurring stomach pain or upset, ulcers, bleeding problems, high blood pressure, heart or kidney disease, other serious medical problems, are currently taking a diuretic, aspirin, anticoagulant, or are &ge;60 years of age. If patients are using for migraines, they should also contact healthcare provider if they have not had a migraine diagnosis by healthcare provider, a headache that is different from usual migraine, worst headache of life, fever and neck stiffness, headache from head injury or coughing, first headache at &ge;50 years of age, daily headache, or migraine requiring bed rest. Recommended dosages should not be exceeded, due to an increased risk of GI bleeding. Stop use and consult a healthcare provider if symptoms get worse, newly appear, fever lasts for &gt;3 days or pain lasts &gt;3 days (children) and &gt;10 days (adults). Do not give for &gt;10 days unless instructed by healthcare provider. Consuming &ge;3 alcoholic beverages/day or taking longer than recommended may increase the risk of GI bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F181500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F181425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Ibuprofen may decrease the serum concentration of Imatinib. Specifically, ibuprofen may decrease intracellular concentrations of imatinib, leading to decreased clinical response.  Management: Consider using an alternative to ibuprofen in patients who are being treated with imatinib.  Available evidence suggests other NSAIDs do not interact in a similar manner.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Ibuprofen. Specifically, concentrations of the S-(+)-ibuprofen enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F181452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Ibuprofen peak serum levels may be decreased if taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F181426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C/D &ge;30 weeks gestation (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7684272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies ibuprofen as pregnancy category C (category D: &ge;30 weeks gestation). NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of a NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including: Myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). Product labeling for Caldolor&reg; specifically notes that use at &ge;30 weeks gestation should be avoided and therefore classifies ibuprofen as pregnancy category D at this time. The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. A registry is available for pregnant women exposed to autoimmune medications including ibuprofen. For additional information contact the Organization of Teratology Information Specialists, OTIS Autoimmune Diseases Study, at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F181467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F181441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on limited data, only very small amounts of ibuprofen are excreted into breast milk. Adverse events have not been reported in nursing infants. Because there is a potential for adverse events to occur in nursing infants, the manufacturer does not recommend the use of ibuprofen while breast-feeding. Use with caution in nursing women with hypertensive disorders of pregnancy or pre-existing renal disease.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F181442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food. Some products may contain phenylalanine and/or potassium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F181440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Advil Migraine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (40): $6.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Advil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (20): $4.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Ibuprofen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (80): $8.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Medi-Profen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (40): $4.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Advil Junior Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (24): $4.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Childrens Motrin Jr Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (24): $4.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Childrens Motrin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (24): $3.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Motrin Junior Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (24): $4.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Caldolor Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg/4 mL (4 mL): $9.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mg/8 mL (8 mL): $13.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (NeoProfen Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (2 mL): $609.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Childrens Advil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/1.25 mL (15 mL): $4.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (120 mL): $5.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Childrens Medi-Profen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (15 mL): $4.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Childrens Motrin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/mL (15 mL): $4.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (120 mL): $5.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Ibuprofen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (120 mL): $9.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Infants Advil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/1.25 mL (15 mL): $4.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Motrin Infants Drops Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/1.25 mL (15 mL): $5.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Motrin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/mL (15 mL): $4.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Advil Junior Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (24): $4.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Advil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (50): $6.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ibuprofen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $4.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $20.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (100): $29.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mg (100): $38.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Medi-Profen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $6.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Motrin IB Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $9.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Motrin Junior Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (24): $4.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Provil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $5.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F181428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, chemistry profile, occult blood loss and periodic liver function tests; monitor response (pain, range of motion, grip strength, mobility, ADL function), inflammation; observe for weight gain, edema; monitor renal function (urine output, serum BUN and creatinine); observe for bleeding, bruising; evaluate gastrointestinal effects (abdominal pain, bleeding, dyspepsia); mental confusion, disorientation; with long-term therapy, periodic ophthalmic exams; signs of infection (ibuprofen lysine)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F181431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Plasma concentrations &gt;200 mcg/mL may be associated with severe toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PDA: Minimum effective concentration: 10-12 mg/L",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F181443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actron (PY, UY);",
"     </li>",
"     <li>",
"      Adex 200 (IL);",
"     </li>",
"     <li>",
"      Adex Liqui-Gels (IL);",
"     </li>",
"     <li>",
"      Advil (AU, BR, CO, CR, DO, EE, ES, FR, GT, HN, IL, MX, NI, PA, PH, PL, SV, VE, ZA);",
"     </li>",
"     <li>",
"      Algofen (IT);",
"     </li>",
"     <li>",
"      Am-Fam 400 (IN);",
"     </li>",
"     <li>",
"      Anafen (ID);",
"     </li>",
"     <li>",
"      Anco (DE);",
"     </li>",
"     <li>",
"      Antarene (FR);",
"     </li>",
"     <li>",
"      Arfen (ID);",
"     </li>",
"     <li>",
"      Balkaprofen (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Bebyzal (KP);",
"     </li>",
"     <li>",
"      Bestafen (MX);",
"     </li>",
"     <li>",
"      Bifen (HK, SG);",
"     </li>",
"     <li>",
"      Brufen (AE, AT, AU, BD, BE, BH, CH, CL, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HK, IE, IQ, IR, IT, JO, JP, KP, KW, LB, LY, MT, MY, NL, NO, NZ, OM, PK, PT, QA, RU, SA, SE, SG, SK, SY, TR, TW, YE, ZA);",
"     </li>",
"     <li>",
"      Brufen 400 (IL);",
"     </li>",
"     <li>",
"      Brufen Syrup for Children (KP);",
"     </li>",
"     <li>",
"      Brufort (IT);",
"     </li>",
"     <li>",
"      Bufect (ID);",
"     </li>",
"     <li>",
"      Bufect Forte (ID);",
"     </li>",
"     <li>",
"      Burana (FI);",
"     </li>",
"     <li>",
"      Carol (KP);",
"     </li>",
"     <li>",
"      Cefen (TH);",
"     </li>",
"     <li>",
"      Cuprofen (TH);",
"     </li>",
"     <li>",
"      Degiton (TW);",
"     </li>",
"     <li>",
"      Diffutab SR 600 (KP);",
"     </li>",
"     <li>",
"      Dolafen (PH);",
"     </li>",
"     <li>",
"      Dolan FP (PH);",
"     </li>",
"     <li>",
"      Dolgit (AE, BH, CY, DE, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Dolocyl (CH);",
"     </li>",
"     <li>",
"      Dolomax (PE);",
"     </li>",
"     <li>",
"      Doloral (PE);",
"     </li>",
"     <li>",
"      Dolormin (DE);",
"     </li>",
"     <li>",
"      Drin (GR);",
"     </li>",
"     <li>",
"      Druisel (AR);",
"     </li>",
"     <li>",
"      Easifon (TW);",
"     </li>",
"     <li>",
"      Expanfen (FR);",
"     </li>",
"     <li>",
"      Febratic (MX);",
"     </li>",
"     <li>",
"      Fenatic (ID);",
"     </li>",
"     <li>",
"      Fenbid (AE, BF, BH, BJ, CI, CY, EG, ET, GB, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Fenpaed (NZ);",
"     </li>",
"     <li>",
"      Fever-Free (PH);",
"     </li>",
"     <li>",
"      Focus (IT);",
"     </li>",
"     <li>",
"      Gesica (TH);",
"     </li>",
"     <li>",
"      Gyno-neuralgin (DE);",
"     </li>",
"     <li>",
"      Ibufac (MY);",
"     </li>",
"     <li>",
"      Ibufen (IL);",
"     </li>",
"     <li>",
"      Ibuflam (MX);",
"     </li>",
"     <li>",
"      Ibufug (DE);",
"     </li>",
"     <li>",
"      Ibugesic (IN);",
"     </li>",
"     <li>",
"      Ibulgan (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GH, GM, GN, GY, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Ibumetin (DK, FI, NL, NO, SE);",
"     </li>",
"     <li>",
"      Ibuped (PH);",
"     </li>",
"     <li>",
"      Ibupirac (AR, CN);",
"     </li>",
"     <li>",
"      Ibuprofen (HK);",
"     </li>",
"     <li>",
"      Ibuprox (ES);",
"     </li>",
"     <li>",
"      Ibusal (FI);",
"     </li>",
"     <li>",
"      Infacalm (HK);",
"     </li>",
"     <li>",
"      Ipren (DK, RU, SE);",
"     </li>",
"     <li>",
"      Iprox (ID);",
"     </li>",
"     <li>",
"      Ipufen (TW);",
"     </li>",
"     <li>",
"      Irfen (AE, BH, CH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Liptan (AE, BH, CY, EG, IL, IQ, IR, JO, JP, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Medicol (PH);",
"     </li>",
"     <li>",
"      Medicol Advance (PH);",
"     </li>",
"     <li>",
"      Mensoton (DE);",
"     </li>",
"     <li>",
"      Mofen (ID);",
"     </li>",
"     <li>",
"      Moris (ID);",
"     </li>",
"     <li>",
"      Moris Forte (ID);",
"     </li>",
"     <li>",
"      Motrin (AE, BH, CO, CR, CY, EC, EG, GT, HN, IQ, IR, JO, KW, LB, LY, MX, NI, OM, PA, PE, QA, SA, SV, SY, YE);",
"     </li>",
"     <li>",
"      Mutrim (PH);",
"     </li>",
"     <li>",
"      Neutropain (HK);",
"     </li>",
"     <li>",
"      Nobafon (TW);",
"     </li>",
"     <li>",
"      Noritis (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Novogent (DE);",
"     </li>",
"     <li>",
"      Nurofen (AT, BE, BF, BG, BJ, CI, CZ, DK, ET, FR, GB, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, SC, SD, SE, SG, SL, SN, TN, TR, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Nurofen for Children (TH);",
"     </li>",
"     <li>",
"      Nurofen Gel (IL, NZ);",
"     </li>",
"     <li>",
"      Nurofen Pro san sucre (FR);",
"     </li>",
"     <li>",
"      Optifen (CH);",
"     </li>",
"     <li>",
"      Opturem (DE);",
"     </li>",
"     <li>",
"      Panafen (NZ);",
"     </li>",
"     <li>",
"      Panafen IB (AU);",
"     </li>",
"     <li>",
"      Pedea (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Perfen (TW);",
"     </li>",
"     <li>",
"      Perofen (BB, BM, BS, BZ, GY, JM, SG, SR, TT);",
"     </li>",
"     <li>",
"      Profen (HK);",
"     </li>",
"     <li>",
"      Proris (ID);",
"     </li>",
"     <li>",
"      Prosinal (ID);",
"     </li>",
"     <li>",
"      Proven (AU);",
"     </li>",
"     <li>",
"      Provon (PE);",
"     </li>",
"     <li>",
"      Quadrax (MX);",
"     </li>",
"     <li>",
"      Rafen (AU);",
"     </li>",
"     <li>",
"      Ranofen (ZA);",
"     </li>",
"     <li>",
"      Rhelafen (ID);",
"     </li>",
"     <li>",
"      Rhelafen Forte (ID);",
"     </li>",
"     <li>",
"      Rupan (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      S-Pro 600 (TH);",
"     </li>",
"     <li>",
"      Spedifen (FR);",
"     </li>",
"     <li>",
"      Speedifen (TH);",
"     </li>",
"     <li>",
"      Spifen (FR);",
"     </li>",
"     <li>",
"      Syntofene (FR);",
"     </li>",
"     <li>",
"      Tabalon 400 (MX);",
"     </li>",
"     <li>",
"      Tarein (TW);",
"     </li>",
"     <li>",
"      Taskine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Tenvalin (EC);",
"     </li>",
"     <li>",
"      Upfen (FR);",
"     </li>",
"     <li>",
"      Uprofen (TW);",
"     </li>",
"     <li>",
"      Urem (DE);",
"     </li>",
"     <li>",
"      Xin Wei (CL);",
"     </li>",
"     <li>",
"      Zofen (MY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F181419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F181437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: Analgesic: 30-60 minutes; Anti-inflammatory: &le;7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid (85%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 6.35 L; premature infants with ductal closure (highly variable between studies):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Day 3: 145-349 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Day 5: 72-222 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90% to 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via oxidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premature infants (highly variable between studies):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 3: 35-51 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 5: 20-33 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 3 months to 10 years: 1.6 &plusmn; 0.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2-4 hours; End-stage renal disease: Unchanged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: ~1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as metabolites; 1% as unchanged drug); some feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brooks PM and Day RO, &ldquo;Nonsteroidal Anti-inflammatory Drugs - Differences and Similarities,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(24):1716-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/2034249/pubmed\" id=\"2034249\" target=\"_blank\">",
"        2034249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al, &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cryer B, Verlin RG, Cooper SA, et al. &ldquo;Double-Blind, Randomized, Parallel, Placebo-Controlled Study Of Ibuprofen Effects On Thromboxane B2 Concentrations In Aspirin-Treated Healthy Adult Volunteers,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2005, 27 (2):185-191.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/15811481/pubmed\" id=\"15811481\" target=\"_blank\">",
"        15811481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies NM, &ldquo;Clinical Pharmacokinetics of Ibuprofen. The First 30 Years,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1998, 34(2):101-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/9515184/pubmed\" id=\"9515184\" target=\"_blank\">",
"        9515184",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gurwitz JH, Avorn J, Ross-Degnan D, et al, &ldquo;Nonsteroidal Anti-inflammatory Drug-Associated Azotemia in the Very Old,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1990, 264(4):471-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/2366280/pubmed\" id=\"2366280\" target=\"_blank\">",
"        2366280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heerdink ER, Leufkens HG, Herings RM, et al, &ldquo;NSAIDs Associated With Increased Risk of Congestive Heart Failure in Elderly Patients Taking Diuretics,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(10):1108-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/9605782/pubmed\" id=\"9605782\" target=\"_blank\">",
"        9605782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holland S, Silberstein SD, Freitag F, et al, &ldquo;Evidence-based Guideline Update: NSAIDs and Other Complementary Treatments for Episodic Migraine Prevention in Adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(17):1346-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/22529203/pubmed\" id=\"22529203\" target=\"_blank\">",
"        22529203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoppmann RA, Peden JG, and Ober SK, &ldquo;Central Nervous System Side Effects of Nonsteroidal Anti-inflammatory Drugs. Aseptic Meningitis, Psychosis, and Cognitive Dysfunction,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1991, 151(7):1309-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/2064481/pubmed\" id=\"2064481\" target=\"_blank\">",
"        2064481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):e1-e90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kauffman RE and Nelson MV, &ldquo;Effect of Age on Ibuprofen Pharmacokinetics and Antipyretic Response,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1992, 121(6):969-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/1447669/pubmed\" id=\"1447669\" target=\"_blank\">",
"        1447669",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Konstan MW, Byard PJ, Hoppel CL, et al, &ldquo;Effect of High-Dose Ibuprofen in Patients With Cystic Fibrosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(13):848-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/7503838/pubmed\" id=\"7503838\" target=\"_blank\">",
"        7503838",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lesko SM and Mitchell AA, &ldquo;An Assessment of the Safety of Pediatric Ibuprofen. A Practitioner-Based Randomized Clinical Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1995, 273(12):929-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/7884951/pubmed\" id=\"7884951\" target=\"_blank\">",
"        7884951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marchei E, Pellegrini M, Pichini S, et al, &ldquo;Are False-Positive Phencyclidine Immunoassay Instant-View Multi-Test Results Caused by Overdose Concentrations of Ibuprofen, Metamizol, and Dextromethorphan?&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 2007, 29(5):671-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/17898664/pubmed\" id=\"17898664\" target=\"_blank\">",
"        17898664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Page J and Henry D, &ldquo;Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2000, 160(6):777-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/10737277/pubmed\" id=\"10737277\" target=\"_blank\">",
"        10737277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pope JE, Anderson JJ, and Felson DT, \"A Meta-analysis of the Effects of Nonsteroidal Anti-Inflammatory Drugs on Blood Pressure,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1993, 153(4):477-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/8435027/pubmed\" id=\"8435027\" target=\"_blank\">",
"        8435027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rollins DE, Jennison TA, and Jones G, &ldquo;Investigation of Interference by Nonsteroidal Anti-Inflammatory Drugs in Urine Tests for Abused Drugs,&rdquo;",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 1990, 36(4):602-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/2323039/pubmed\" id=\"2323039\" target=\"_blank\">",
"        2323039",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuijt MP, Huntjens-Fleuren HW, de Metz M, et al, \"The Interaction of Ibuprofen and Diclofenac With Aspirin in Healthy Volunteers,\"",
"      <i>",
"       Br J Pharmacol",
"      </i>",
"      , 2009, 157(6):931-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/1946698/pubmed\" id=\"1946698\" target=\"_blank\">",
"        1946698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steinhubl SR, &ldquo;The Use of Anti-Inflammatory Analgesics in the Patient With Cardiovascular Disease: What a Pain,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1302-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/15837266/pubmed\" id=\"15837266\" target=\"_blank\">",
"        15837266",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Overmeire B, &ldquo;The Use of Ibuprofen in Neonates in the Treatment of Patent Ductus Arteriosus,&rdquo;",
"      <i>",
"       Int J Clin Pract Suppl",
"      </i>",
"      , 2003, (135):23-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/12723743/pubmed\" id=\"12723743\" target=\"_blank\">",
"        12723743",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Overmeire B, Smets K, Lecoutere D, et al, &ldquo;A Comparison of Ibuprofen and Indomethacin for Closure of Patent Ductus Arteriosus,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 343(10):674-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/10974130/pubmed\" id=\"10974130\" target=\"_blank\">",
"        10974130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Overmeire B, Touw D, Schepens PJ, et al, &ldquo;Ibuprofen Pharmacokinetics in Preterm Infants With Patent Ductus Arteriosus,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2001, 70(4):336-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/11673749/pubmed\" id=\"11673749\" target=\"_blank\">",
"        11673749",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verbeeck RK, &ldquo;Pharmacokinetic Drug Interactions With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1990, 19(1):44-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/38/15978/abstract-text/2199127/pubmed\" id=\"2199127\" target=\"_blank\">",
"        2199127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8547 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-37B631BF3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_38_15978=[""].join("\n");
var outline_f15_38_15978=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708913\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181456\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181457\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181507\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181461\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181483\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181462\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6784600\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181463\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181430\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181416\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874617\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181435\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985823\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181434\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181503\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181516\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181505\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181438\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181420\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181500\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181425\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181452\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181426\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7684272\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181467\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181441\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181442\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181440\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181428\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181431\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181443\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181419\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181437\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8547\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8547|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=related_link\">",
"      Ibuprofen: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=related_link\">",
"      Ibuprofen: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_38_15979="Fetal testing for thalassemia";
var content_f15_38_15979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Results of fetal DNA testing for thalassemia major syndromes, June 1974 - December 1989",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of cases",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total cases at risk for thalassemia",
"       </td>",
"       <td>",
"        4300",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Affected cases",
"       </td>",
"       <td>",
"        1074",
"       </td>",
"       <td>",
"        25.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancies continued",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        2.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fetal losses",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        1.2*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnostic errors",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        0.5*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Data from 6300 cases tested for either thalassemia or sickle cell disease.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission by Beris, P, et al. Prevention of beta-thalassemia. Semin Hematol 1995; 32:244.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_38_15979=[""].join("\n");
var outline_f15_38_15979=null;
var title_f15_38_15980="Criteria periodic health exam";
var content_f15_38_15980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for deciding whether a medical condition should be included in periodic health examinations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"1\" rowspan=\"1\">",
"       1. How great is the burden of suffering caused by the condition in terms of:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Death",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disability",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Discomfort",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dissatisfaction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Destitution",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"1\" rowspan=\"1\">",
"       2. How good is the screening test, if one is to be performed, in terms of:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sensitivity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Specificity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Simplicity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Labeling effects",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cost",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Safety",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acceptability",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"1\" rowspan=\"1\">",
"       3. How good is the preventive treatment?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Primary prevention: How good is the intervention in terms of:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"1\" rowspan=\"1\">",
"       Effectiveness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"1\" rowspan=\"1\">",
"       Safety",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"1\" rowspan=\"1\">",
"       Cost-effectiveness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"1\" rowspan=\"1\">",
"       Secondary prevention- If the condition is found, how effective is the ensuing treatment in terms of:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"1\" rowspan=\"1\">",
"       Effectiveness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"1\" rowspan=\"1\">",
"       Safety",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"1\" rowspan=\"1\">",
"       Early treatment being more effective than later treatment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"1\" rowspan=\"1\">",
"       Cost-effectiveness",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher RF, Fletcher SW. Prevention. In: Clinical Epidemiology: The Essentials, 4th Ed, Lippincott Williams &amp; Wilkins, Baltimore 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_38_15980=[""].join("\n");
var outline_f15_38_15980=null;
var title_f15_38_15981="Features of malaria spp";
var content_f15_38_15981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparing the malaria species",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       P. falciparum",
"      </td>",
"      <td class=\"subtitle1\">",
"       P. vivax",
"      </td>",
"      <td class=\"subtitle1\">",
"       P. ovale",
"      </td>",
"      <td class=\"subtitle1\">",
"       P. malariae",
"      </td>",
"      <td class=\"subtitle1\">",
"       P. knowlesi",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Geography",
"      </td>",
"      <td>",
"       Tropical, temperate zones",
"      </td>",
"      <td>",
"       Tropical, temperate zones, absent from West Africa",
"      </td>",
"      <td>",
"       Tropical, endemic in West Africa, present in Philippines, Indonesia, and Papua New Guinea",
"      </td>",
"      <td>",
"       Tropical, isolated pockets",
"      </td>",
"      <td>",
"       South and Southeast Asia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       RBC preference",
"      </td>",
"      <td>",
"       RBCs of all ages",
"      </td>",
"      <td>",
"       Young RBCs (reticulocytes)",
"      </td>",
"      <td>",
"       Young RBCs (reticulocytes)",
"      </td>",
"      <td>",
"       Older RBCs",
"      </td>",
"      <td>",
"       RBCs of all ages",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infected RBC diameter",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       Larger than normal",
"      </td>",
"      <td>",
"       Larger than normal",
"      </td>",
"      <td>",
"       Normal or smaller than normal",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ameboid trophozoites",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Band forms",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Schizont*",
"      </td>",
"      <td>",
"       16 to 20 merozoites; very rare in peripheral circulation",
"      </td>",
"      <td>",
"       20 to 24 merozoites",
"      </td>",
"      <td>",
"       4 to 16 merozoites (8 typical)",
"      </td>",
"      <td>",
"       6 to 12 merozoites (8 or 10 typical)",
"      </td>",
"      <td>",
"       8 to 16 (10 typical)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parasitemia",
"      </td>",
"      <td>",
"       Can be very high",
"      </td>",
"      <td>",
"       Usually &lt;2 percent",
"      </td>",
"      <td>",
"       Usually &lt;2 percent",
"      </td>",
"      <td>",
"       Usually very low",
"      </td>",
"      <td>",
"       Can be high",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disease severity",
"      </td>",
"      <td>",
"       End organ damage and death can occur",
"      </td>",
"      <td>",
"       End organ damage and death less common than P. falciparum but can occur",
"      </td>",
"      <td>",
"       Severe disease uncommon",
"      </td>",
"      <td>",
"       Severe disease rare",
"      </td>",
"      <td>",
"       Severe disease can occur",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chloroquine resistance",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       Rare",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Relapses from liver",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       No",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Incubation period",
"      </td>",
"      <td>",
"       12 days (8 to 25)",
"      </td>",
"      <td>",
"       14 days (10 to 30) (occasionally months)",
"      </td>",
"      <td>",
"       15 days (10 to 20)",
"      </td>",
"      <td>",
"       18 days (15 to 35) (occasionally months to years)",
"      </td>",
"      <td>",
"       Uncertain in naturally infected humans",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Prepatent period in liver",
"      </td>",
"      <td>",
"       11 days",
"      </td>",
"      <td>",
"       12 days&bull;",
"      </td>",
"      <td>",
"       12 days",
"      </td>",
"      <td>",
"       32 days",
"      </td>",
"      <td>",
"       Uncertain in naturally infected humans",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cycle in red cell",
"      </td>",
"      <td>",
"       48 hours",
"      </td>",
"      <td>",
"       48 hours",
"      </td>",
"      <td>",
"       48 hours",
"      </td>",
"      <td>",
"       72 hours",
"      </td>",
"      <td>",
"       Uncertain in naturally infected humans",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Identification of a schizont with &gt;12 merozoites in the peripheral circulation is an important diagnostic clue for P. vivax. In general, schizonts of P. falciparum are very rarely seen in blood films; they occur only in the setting of severe disease with hyperparasitemia.",
"     <br>",
"      &bull; The latency period of vivax is typically longer than falciparum: file://www.cdc.gov/mmwr/preview/mmwrhtml/ss5606a2.htm (see table summarizing time to symptoms for each species).",
"      <br>",
"       RBC: red blood cell.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_38_15981=[""].join("\n");
var outline_f15_38_15981=null;
var title_f15_38_15982="Summary of meta analyses of heart failure management programs";
var content_f15_38_15982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary results from meta analyses of heart failure disease management programs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         All types of chronic disease management",
"        </p>",
"        <p>",
"         RR (95% CI)",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        N",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Specialized follow-up by multidisciplinary team",
"        </p>",
"        <p>",
"         RR (95% CI)",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        N",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Telephone contact and improved coordination of primary care services",
"        </p>",
"        <p>",
"         RR (95% CI)",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        N",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Enhanced self-care or patient education",
"        </p>",
"        <p>",
"         RR (95% CI)",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <strong>",
"         Mortality",
"        </strong>",
"       </td>",
"       <td>",
"        0.94 (0.75-1.19)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        2067",
"       </td>",
"       <td>",
"        0.75 (0.59-0.96)",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        946",
"       </td>",
"       <td>",
"        0.91 (0.67-1.29)",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        1193",
"       </td>",
"       <td>",
"        1.14 (0.67-1.94)",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        459",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.80 (0.69, 0.93)",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        5308",
"       </td>",
"       <td>",
"        0.98 (0.72-1.34)",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        1039",
"       </td>",
"       <td>",
"        0.85 (0.72-1.01)",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        3542",
"       </td>",
"       <td>",
"        0.87 (0.72-1.06)",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        3238",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        0.88 (0.76-1.01)",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        5563",
"       </td>",
"       <td>",
"        0.93 (0.57-1.51)",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"       <td>",
"        385",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        <strong>",
"         All cause hospitalization",
"        </strong>",
"       </td>",
"       <td>",
"        0.88 (0.79-0.97)",
"        <sup>",
"         [9]",
"        </sup>",
"       </td>",
"       <td>",
"        4440",
"       </td>",
"       <td>",
"        0.77 (0.68-0.86)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        1366",
"       </td>",
"       <td>",
"        1.15 (0.96-1.37)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        646",
"       </td>",
"       <td>",
"        0.73 (0.57-0.93)",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        459",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.87 (0.79-0.96)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        2067",
"       </td>",
"       <td>",
"        0.81 (0.71-0.92)",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        1145",
"       </td>",
"       <td>",
"        0.98 (0.80-1.20)",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        1581",
"       </td>",
"       <td>",
"        0.80 (0.71-0.89)",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        1519",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.80 (0.68-0.94)",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        4603",
"       </td>",
"       <td>",
"        0.79 (0.68-0.91)",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        1246",
"       </td>",
"       <td>",
"        0.94 (0.87-1.02)",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        3200",
"       </td>",
"       <td>",
"        0.59 (0.44-0.80)",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"       <td>",
"        787",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        0.86 (0.73-1.02)",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        3349",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.92 (0.95-0.99)",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        4295",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         Heart failure hospitalization",
"        </strong>",
"       </td>",
"       <td>",
"        0.70 (0.62-0.79)",
"        <sup>",
"         [9]",
"        </sup>",
"       </td>",
"       <td>",
"        3160",
"       </td>",
"       <td>",
"        0.74 (0.63-0.87)",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        657",
"       </td>",
"       <td>",
"        0.75 (0.57-0.99)",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        1024",
"       </td>",
"       <td>",
"        0.66 (0.52-0.83)",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        568",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        0.78 (0.68-0.89)",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        3268",
"       </td>",
"       <td>",
"        0.44 (0.27-0.71)",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"       <td>",
"        381",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.77 (0.68-0.87)",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        4269",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Combined mortality and hospitalization",
"        </strong>",
"       </td>",
"       <td>",
"        0.82 (0.72-0.94)",
"        <sup>",
"         [9]",
"        </sup>",
"       </td>",
"       <td>",
"        2985",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001; 110:378.",
"       </li>",
"       <li>",
"        Roccaforte R, Demers C, Baldassarre F, et al. Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis. Eur J Heart Fail 2005; 7:1133.",
"       </li>",
"       <li>",
"        McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004; 44:810.",
"       </li>",
"       <li>",
"        Gwadry-Sridhar FH, Flintoft V, Lee DS, et al. A systematic review and meta-analysis of studies comparing readmission rates and mortality rates in patients with heart failure. Arch Intern Med 2004; 164:2315.",
"       </li>",
"       <li>",
"        Clark RA, Inglis SC, McAlister FA, et al. Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. BMJ 2007; 334:942.",
"       </li>",
"       <li>",
"        Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev 2010; 8:CD007228.",
"       </li>",
"       <li>",
"        Holland R, Battersby J, Harvey I, et al. Systematic review of multidisciplinary interventions in heart failure. Heart 2005; 91:899.",
"       </li>",
"       <li>",
"        Jovicic A, Holroyd-Leduc JM, Straus SE. Effects of self-management intervention on health outcomes of patients with heart failure: a systematic review of randomized controlled trials. BMC Cardiovasc Disord 2006; 6:43.",
"       </li>",
"       <li>",
"        Gonseth J, Guallar-Castillon P, Banegas JR, Rodriguez-Artalejo F. The effectiveness of disease management programmes in reducing hospital re-admission in older patients with heart failure: a systematic review and meta-analysis of published reports. Eur Heart J 2004; 25:1570.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_38_15982=[""].join("\n");
var outline_f15_38_15982=null;
var title_f15_38_15983="Management of suspected preterm labor";
var content_f15_38_15983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 598px\">",
"   <div class=\"ttl\">",
"    Management of suspected preterm labor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 578px; height: 554px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: Iams JD. Prediction and early detection of preterm labor. Obstet Gynecol 2003; 101:402.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_38_15983=[""].join("\n");
var outline_f15_38_15983=null;
